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Abstract

Hepatocellular carcinoma is one of the most common health problems that is difficult
to treat. As a result of the side effects frequently experienced with conventional
cancer treatments, there has been a growing interest to develop controlled drug
delivery system that can reduce the mortality rate of liver cancer patients and unharm healthy tissues. Magnetite nanoparticles are potentially important in
hepatocellular carcinoma treatment, since they can be used as delivery system. Pure
and coated magnetite nanoparticles were synthesized via modified co-precipitation
method in air at low temperature. Various reaction parameters and coating materials
have been investigated and characterized. Among these parameters and coating
materials, 1.0 % of dextran was selected as an optimum coating for nanoparticles
using a slow feeding rate for the Fe2+/Fe3+ reactants, maintaining the stirring and
soaking temperatures at 60ºC. After that dextran-coated magnetite nanoparticles were
bound to crocin, a pharmacologically active component of saffron, via cross-linker.
Crocin alone has shown anti-cancer activity in different in vitro and in vivo settings
by several studies. The aim of this study was to synthesize dextran-coated magnetite
nanoparticles containing crocin with a higher therapeutic index for hepatocellular
carcinoma treatment. The nanoparticles with crocin were tested in vitro and in vivo
for their anti-cancer effects as compared to free crocin. HepG2 cells treated with
crocin-dextran-coated magnetite nanoparticles showed a decrease in cell proliferation
compared to control (non-treated cells) or to those treated with free crocin or
dextran-coated nanoparticles. The anti-cancer activity of crocin-dextran-coated
nanoparticles was also evaluated in Balb/c mice. These mice were injected with
carcinogenic agent, diethylnitrosamine. Histological examination revealed several

vii

precancerous changes. The immunohistochemical analysis using antibodies
indication of cell proliferation (Ki-67), apoptosis (M30-Cytodeath and Bcl-2),
inflammation (cyclooxygenase-2) and angiogenesis (vascular endothelial growth
factor), indicated that magnetite nanoparticles conjugated with dextran plus crocin
does indeed improve its anti-tumorigenic activity over free crocin. These results
provide the basis for designing new modalities for treatment of liver cancer which
could hopefully reduce its high mortality rate.

Keywords: Magnetite nanoparticles, dextran, precancerous changes, crocin,
diethylnitrosamine, immunohistochemical studies.
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)Title and Abstract (in Arabic
إنشاء نموذج لعالج سرطان الكبد المبكر باستخدام جزيئات النانو الممغنطة و المغلفة بالكروسين ()oicorc

الملخص
يعتبر سرطان الكبد من اكثر المشاكل الصحية شيوعا التي يصعب عالجها .ونتيجة آلثار الجانبية التي
عادة ما تصاحب وسائل العالج التقليدية للسرطان ,فقد كان هناك اهتمام متزايد لتطوير نظام التحكم في توجيه
وتوصيل االدوية إلى مكان السرطان التي يمكن أن تقلل من معدل الوفيات بسرطان الكبد وال تحدث ضرر
باألنسجة السليمة .جزئيات النانو الممغنطة يمكن أن تكون مهمة لعالج سرطان الكبد لما لها من دور في زيادة
كفاءة توجيه وتوصيل األدوية .تم تحضير جزئيات النانو الممغنطة النقية والمغلفة بطريقة خاصة ومعدلة في
الهواء وفي درجة حرارة منخفضة .كما تم دراسة مختلف عوامل ومعايير التفاعل ومواد التغليف .ومن بين
العديد من تلك المعايير ومواد التغليف ,فقد اختير  %1.0من الديكستران ( )nartxedكالتلغليف األمثل لجزيئات
النانو باستخدام معدل تنزيل بطيء للحديد الثنائي والثالثي مع الحفاظ على درجات حرارة التحريك والتنقيع في
 60درجة مئوية .وبعد ذلك تم تحضير جزيئات النانو الممغنطة والمغلفة بالديكستران و بالكروسين .الكروسين
هو العقار النشط في نبات الزعفران .وقد أثبت الكروسين عند استخدامه بمفرده قدرته في مكافحة السرطان في
مختلف التجارب المخبرية بواسطة العديد من الدراسات.
وكان الهدف من هذه الدراسة هو انتاج جزيئات النانو الممغنطة و المغلفة بالديكستران والتي تحتوي
على الكروسين ودراسة قدرتها العالجية لسرطان الكبد حيث تم اختبار قدرة جزيئات النانو مع الكروسين في
المختبر .ولقد تم اختبار قدرة جزيئات النانو مع الكروسين في المختبر على مكافحة السرطان .و لوحظ أن
الخاليا السرطانية للكبد ( )HepG2تراجعت في تكاثرها بعد معالجتها بجزيئات النانو المغلفة بالديكستران و
الكروسين مقارنة مع الخاليا الغير معالجة ,أو الخاليا المعالجة بالكروسين بمفرده أو بجزيئات النانو المغلفة
بالديكستران وبدون الكروسين .كما تم تقييم قدرة جزيئات النانو المغلفة بالديكستران و الكروسين على مكافحة
السرطان في فئران التجارب ( .)Balb/cحيث تم حقنها بمادة مسرطنة ( . (diethylnitrosamineوكشف

الفحص النسيجي على تواجد العديد من التغيرات المصاحبة للمراحل األولى من االصابه بالسرطان .كما أشار التحليل
الكيمياء النسيجي المناعي ( )immunohistochemicalباستخدام األجسام المضادة المعنية بالتعرف على
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عامل التكاثر الخلوي ( ,)Ki-67وعامل موت الخاليا المبرمج ( , )M30-Cytodeath and Bcl-2وعامل
االلتهابات الخلوية ) (cyclooxygenase-2وعامل نمو األوعية الدموية الجديدة ( vascular endothelial
 )growth factorإلى أن جزيئات النانو المغلفة بالديكستران والكروسين أظهرت تحسنا ملموسا في مكافحة
السرطان مقارنة بالكروسين بمفرده .تمثل تلك النتائج األساس لتصميم طرق جديدة لعالج سرطان الكبد الذي
نأمل في أن يساهم في خفض معدالت الوفيات المرتفعة لهذا المرض العضال.

الكلمات الرئيسية :جزيئات النانو الممغنطة ,ديكستران ,التغيرات المصاحبة للمراحل األولى من االصابة
بالسرطان ,كروسين ,المادة المسرطنة  ,diethylnitrosamineدراسات التحليل الكيميائي النسيجي المناعي.
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Chapter 1: Introduction

1.1. Cancer
Cancer is a disease characterized by cells that uncontrollably outgrow their
normal counterparts. The terms tumor and cancer are sometimes used synonymously,
which can be misleading. A tumor is not necessarily a cancer. The word tumor refers
to a mass or lumps that may refer to benign or malignant growths. Neoplasm is a
synonym of tumor. A benign tumor is a non-malignant/non-cancerous tumor and is
usually localized, grows slowly, and rarely spreads to other parts of the body.
Malignant tumor is however, a cancer that is resistant to treatment, invades adjoining
parts of the body, and might reoccur after removal [1, 2]. There are several hallmarks
of cancer cells include stimulate their own growth, resist growth inhibitory signals,
avoid apoptosis, stimulate angiogenesis, multiply endless by invade adjacent tissues
and metastasize, and avoiding immune destruction [1, 2].
Cancer is among the leading causes of death worldwide, accounting for 8.2
million deaths and 32.6 million people living and suffering from cancer in 2012
alone. It was estimated that annual cancer cases would rise from 14 million in 2012
to 22 million within the next two decades. The most common causes of cancer death
are lung [3], liver (745 000 deaths), stomach (723 000 deaths), colorectal (694 000
deaths) and breast (521 000 deaths) cancers [4]. In the United Arab Emirates (UAE)
cancer is the third leading cause of death after cardiovascular diseases and accidents.
Data from the Health Authority of Abu Dhabi indicated that cancer accounts for
approximately 474 deaths cases in 2012, with 53% male and 47% female, and the
majority are expatriates. Millions of dirhams are invested annually to treat cancer
cases in the UAE [5]. There are over 100 different types of cancer, and each
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classified according to the type of cell that is initially affected. Each organ consists of
different cell types that may affected by cancer. Liver is one of the vital organs that
might develop cancer.
1.2. Liver
The liver is a vital organ of the digestive system. It is the largest gland in the
body and the heaviest internal organ (1200-1500 g). It maintains many of the body’s
homeostatic and physiological functions. The liver receives all absorbed substances
from intestine where some foreign material may filter via portal vein. Systemically it
receives it’s oxygen via arterial blood supply (hepatic artery). The liver stores the
nutrients and controls their release to the systemic circulation [6-9].
Liver functions are various and can be categorized into metabolic, catabolic,
synthetic, storage and excretory functions. The liver has a central role in the
regulation of metabolism of nutrients like carbohydrate (glycogenolysis and
gluconeogenesis), protein, fat, hormone and various xenobiotics, such as food
additives, drugs, or environmental pollutants. Liver produces albumin, blood
coagulation factors, vitamins like vitamin A and iron. In addition, it sores glycogen,
triglycerides, iron, copper and lipid soluble vitamins. It also catabolizes endogenous
substance including hormones, serum proteins, old red blood cells, haemoglobin and
bilirubin and maintain a balance between their production and removal. Drugs are
catabolized and detoxified, then excreted via the kidney or the biliary system. The
main excretory product of the liver is bile while stored in the gallbladder. The bile
helps in heme catabolism and absorption of fat in the small intestine [8, 9].
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1.2.1. Liver structure
The liver consists of multiple lobes; left, right (the largest), caudate, and
quadrate or middle lobes. Caudate and quadrate lobes are located in the back of right
lobe. Parietal and visceral surfaces of the liver are cover by a capsule. It is a thin
connective tissue layer covered by peritoneal mesothelial cells. Liver has a dual
blood supply, the hepatic portal vein and hepatic artery [10].
The histological or structural unit of the liver is a polyhedral anatomical
lobules (Figure 1). Each lobule contains a central vein, and radiating sinusoids
separated from each other by plates of hepatocytes, and peripheral portal tracts or
triads. Portal triad includes branches of hepatic artery, portal vein and bile duct. The
blood flows from portal vein into central vein, and the branches of central veins unit
to form three main veins that enter the inferior vena cava. The bile flows in opposite
direction from hepatocytes into the bile ducts and eventually store in gall bladder
[10].
The main parenchymal cellular units of the liver are hepatocytes. The
hepatocytes are arranged in plates or cords that radiate from the central vein to the
portal areas (Figure 1). Hepatocytes, on one side, they are separated from the
sinusoidal wall by space of Disse, where they are exposed to tissue cytoplasm. On
the opposite side, bile canaliculi are formed with hepatocytes in an adjacent hepatic
cord. Desmosomes, and gap junctions connect neighbouring hepatocytes within a
plate. In addition to hepatocytes and blood cells that exist in the sinusoids and blood
vessels, the liver includes several other types of cells, including biliary duct cells,
oval cells, endothelial cells, Kupffer cells, Ito cells (stellate cells), and pit cells [10].
Biliary cells form the bile ducts in the portal areas. Oval cells are stem cells
located in Herring canals, the area where the biliary duct system connected with
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hepatocytes. It has been shown that oval cells have a potency to generate and
regenerate not only hepatocytes after injury, but also bile duct cells, intestinal
epithelium and pancreatic acinar cells [9-11]. Fenestrated endothelial cells line the
sinusoids and synthesize prostaglandins [10]. Kuppfer cells are mononuclear
macrophages forming 10% of all liver cells. These cells are phagocytic,
inflammation mediators, and catabolize lipids and proteins. They are also essential
for paracrine interactions between hepatocytes and Ito cells. Ito cells are perisinusoidal cells that store vitamin A and fat and are the main source of collagen in
the liver. Pit cells are lymphocytes that have characteristic features of natural killer
cells and therefore exert cytotoxic activity against tumor cells, and are mostly located
in periportal areas [10].
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Figure 1: Diagrammatic representation of anatomical lobule which is the structural
unit of the liver. Each lobule includes plates of hepatocytes, hepatic sinusoidal
endothelial cells (HSEC); Hepatic stellate cells (HSC), and kupffer cells [12].
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1.2.2. Liver neoplasm
Despite the liver capacity for regenerative growth by oval cells, it is a target
organ for damage induced by a variety of factors such as toxins, alcohol, chronic
inflammations, drugs, and genetic mutations. These may lead to various liver
diseases including acute liver failure, viral hepatitis, cirrhosis, steatosis or fibrosis. If
these diseases not treated early, may lead to development of liver cancer. Primary
liver cancer occurs in different form, such as hepatocellular carcinoma (HCC),
intrahepatic cholangiocarcinoma (ICC) and hepatoblastoma [13].
1.2.2.1. HCC
HCC is one of the most common primary malignant liver lesions, accounting
for 70-80% of primary liver cancer cases [13, 14]. HCC is the fifth common cancer
in the world. It kills almost half-million people around the world every year, and it
is the third most common cause of cancer-related deaths [13-17]. The Health
Authority of Abu Dhabi reported in 2013 that in UAE there are 17% of cancer
patients died because of liver cancer and ICC. Among these patients 13% are men
and 4 % women [5].
About 80% of HCC develop in cirrhotic livers and chronic hepatitis. Chronic
viral infections, including the hepatitis B and hepatitis C viruses are major risk
factors contributing to HCC development. Hepatitis B virus infection is most
relevant in most parts of Asia and Africa, with ingestion of aflatoxin B1 from
contaminated food an additional contributory factor. In the West and Japan, hepatitis
C virus infection is the main risk factor. Apart from hepatotropic viruses, other major
risk factor leading to cirrhosis includes excess alcohol intake. HCC is an aggressive
cancer with a poor prognosis [14, 17-21].
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Late diagnosis of HCC usually leads to a very short survival time. Enhancing
the survival rate requires detection of small tumors at early stages, often present in
asymptomatic individuals. Ultrasonography is the preferred imaging method for
screening, because it can be tolerated and widely accessible. However,
ultrasonography sensitivity for HCC detection is low, because small nodules can be
easily missed in a cirrhotic liver. Contrast-enhanced ultrasonography can be used to
improve the diagnostic performance of ultrasonography for HCC. The most common
used serological test for screening is alpha-fetoprotein, but it is no longer considered
as a surveillance test because of its low sensitivity. Contrast-enhanced computed
tomography and magnetic resonance imaging (MRI) have a high sensitivity (55%–
91%) and specificity (77%–96%) in diagnosing HCC. The diagnosis of HCC lesions
measuring between 1 and 2 cm is confirmed when typical vascular pattern detected
on CT and MRI. Otherwise, these lesions should not be treated as HCC without
histological indication because of a rate of false positives is as high as 20% [19, 21,
22].
Therapeutic strategies for HCC patients include surgical resection or liver
transplantation, which are only applicable to a small proportion of patients around
25% with early tumors. Other therapeutic methods are percutaneous ethanol
injection, percutaneous radiofrequency ablation, and trans-arterial embolization. Due
to late detection and advanced underlying liver diseases, these treatments are
normally not recommended to the majority of the patients [18, 22-24].
Regarding the chemotherapy, the only drug that is currently being used for
HCC is sorafenib. However, the patients survival remains low, and sorafenib may
only improve life expectancy by approximately 3 months over placebo control [18,
22-24]. Sorafenib (also known as Nexavar), is a multikinase inhibitor that targets the
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vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and
platelet-derived growth factor receptor family (PDGFR-beta). These receptors play
key roles in cancer progression. It also inhibits activation of oncogenic RAF
serine/threonine

kinases

along

the

RAF/MEK/ERK

pathway

(Ras/RAF

pathway), which will inhibit proliferative signal resulting in blocking in tumour
growth and development [25].
Prior sorafenib, doxorubicin was routinely used as a single drug for advanced
HCC, but has been shown ineffective, with a response rate of about 15-20% [26].
Other chemotherapy agents, such as epirubicin, cisplatin, 5-fluorouracil, etoposide
and their combinations, demonstrate even lower efficacy [18, 22, 23, 26].
One of the main reasons for which the patients with HCC have poor
prognosis is the multicentric occurrence of HCC in the liver of patients with chronic
hepatitis or cirrhosis caused by infection of hepatitis viruses. Thus, even if the first
cancer is diagnosed and removed another malignant cell clone may arise to form a
second primary cancer (Moriwaki, 2002). Therefore, due to the fact that the current
treatments for HCC are not effective, new strategies are needed not only to prevent
the development or post-therapeutic recurrence of HCC but also to prevent further
deterioration of liver function [22-24, 27].
1.3. Liver neoplasm and Animal Model
The increase in the burden of liver cancer and specifically HCC require
understanding the aetiology, cellular and molecular mechanisms leading to it. Thus,
the development of animal models for better understanding is essential [13, 14, 16].
Currently, a wide range of HCC animal models are existing, which have provided
researchers with the opportunity to: 1) evaluate cancer–host interactions, 2) perform
drug screening and testing, 3) mimic the complex multistep process of liver
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carcinogenesis in human, and 4) conduct various therapeutic experiments [13, 14, 16;
28].
Mice models are one of the preferred and convenient experimental systems,
owing to the physiologic, molecular and genetic similarities to humans, their
breeding capacity, short lifespan, affordable, easier to be handle and the unlimited
options offered by genetic engineering. Mice are also small, easily housed, and
maintained, and adapt well to the new surroundings [13, 16]. There are many ways
to produce HCC using mice models, such as chemically-induced, xenograft
implantation and genetically modified models [17].
1.3.1. Chemically-induced models
Several chemical reagents induce liver damage and HCC formation and
development of tumours when timely administered in sufficient doses. There are two
types of carcinogens: (1) Genotoxic compounds which are characterized by their
ability to induce direct structural DNA changes. (2) Promoting compounds which
enhance tumour formation after initiation, and lack direct genotoxic capability.
Treatment with tumour promoting agent facilitates the clonal expansion of the
preneoplastic cells. The advantage of chemically-induced models is that it mimics
pathological events such as injury and malignancy steps that occur in humans. This
makes them the preferred models for HCC research [13, 28].
1.3.1.1. Diethylnitrosamine
As mentioned earlier liver is the primary target location for many chemicals
including pesticides, food additives, pharmaceuticals and industrial intermediates
[13].

The

genotoxic

diethylnitrosamine

compound

(DEN),

is

N-Nitrosodiethylamin,

categorized

as

a

potent

also

known

hepatotoxin

as
and

hepatocarcinogen producing reproducible tumors after repeated administration in
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experimental animals. DEN induces lesions in animals that mimic the process of
different types of malignant cancers in human [29].
In 1956, the British John Barnes and Peter Magee are the first scientists who
reported that DEN produced liver tumours in rats during toxicity screening test of
chemicals. These chemicals were being proposed for the use as solvents in the dry
cleaning industry [30]. DEN belongs to nitrosamine family. This family is
structurally divided into N-nitrosamides and N-nitrosodialkylamines and both groups
can induce DNA damage. DEN belongs to N-nitrosodialkylamines that require
metabolic activation mediated by cytochrome P450 (CYP450) enzymes, in order to
induce DNA damage. It is a slightly yellow liquid and soluble in water, saline,
ethanol, diethyl ether and organic solvents [31, 32].
As DEN is known to produce cancer in many different species and due to its
widespread occurrence in a variety of products consumed by human, the possibility
of DEN being a main cause of cancer in humans has been the concern of public
health agencies for a long time. DEN is found in various foods like cheese, milk and
diary product, soybean, smoked, salted and dried fish, cured meat, fried bacon, soft
drinks and alcoholic beverages like whiskey and beers [29, 32, 33]. DEN is also
found in tobacco smoke at a concentration ranging from 1 to 28 ng/cigarette, and in
baby bottle nipples at a level of 10 ppb. It is used also in the production of some
cosmetics, pesticides, metal industry, and in most rubber and latex products such as
balloons [29, 31].
DEN is metabolically activated to carcinogens by CYP2E1 isoforms (one of
CYP450 enzymes). This isoform is highly conserved, having a high degree of
sequence homology between various species, including humans. DEN causes
carcinogenic activity in several different ways as the following:

11

1)

DEN has capability of alkylating DNA structures leading to the formation of

mutagenic DNA adducts. In the first step, DEN is hydroxylated to ahydroxylnitrosamine. This bio-activation step is oxygen- and NADPH- dependent.
An electrophilic ethyldiazonium ion is formed post cleavage of acetaldehyde. This
ethyldiazonium ion causes DNA damage by reacting with DNA-bases. The resulting
O6-ethylguanine leads to GC–AT transitions [16, 31, 34].
2)

DEN can cause reactive oxygen species (ROS) formation. The generated

ROS including hydrogen peroxide and superoxide anions induce oxidative stress and
cause carcinogenesis by destroying DNA, protein and lipid [13, 16, 17, 33].
Oxidative stress plays a vital role in hepatocarcinogenesis, particularly in the
initiation and progression steps. ROS-mediated DNA damage is associated with
breaks in single or double stranded DNA chain, and alterations in deoxyribose or
nitrogenous bases. Such increased erroneous replication will lead to genomic
instability and eventually causing carcinogenesis [34].
3)

DEN develops cancer by inducing mutations in H-ras proto-oncogene (also

known as Ha-ras gene). The mutation in H-ras gene was attributed to specific singlebase substitutions at different bases of codon 61. These point mutations either a
transversion in the first base (substitution of a purine (A and G) for a pyrimidine (C
and T) or vice versa), or a transition in the second base (substitution of a purine for
a purine, or pyrimidine for another pyrimidine) [35, 36]. H-ras gene produces H-ras
protein that is involved in regulating normal cell division and proliferation in
response to growth factor stimulation like epidermal growth factor (EGF). Then
activates major effector pathways necessary for the propagation of the receptor's
signal, such as Raf protein kinases and phosphatidyl inositol 3-kinase (PI3K). Raf
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regulates cell cycle progression and transcription, and PI3K plays an impoetant role
in reguatling cell grwoth, proliferation and survival [37].
4)

DEN alone leads to the formation of lesions that overexpress the Bcl-2 gene
[17].

5)

DEN stimulates the proliferation of hepatic oval cells and bile duct cells
leading to hyperplasia and the formation of microscopic intrahepatic
cholangioma [38, 39].
The target organ in which DEN generates tumours is species specific.

Hartwell and Shubik are the first who compiled a review of DEN carcinogenicity
examining in between 1961-1967. Upon DEN exposure, mice have been shown to
develop manily HCC, in addition to gastrointestinal, skin, respiratory and
haematopoietic tumours. Rats were also primarily HCC, besides gastrointestinal
cancer. Guinea pigs and Syrian hamsters developed HCC, gastrointestinal and
respiratory cancer. Rabbits, dogs and monkeys had only HCC while pigs had both
HCC and hematopoietic cancer [17, 40].
The time needed after DEN adminstration to develop HCC depend on sevral
factors, including: dose concentration, gender, age, animal strain, dose repetitive
administration, administration period (short or long term), route of adminstration, and
individaul DEN injection or in association with promoting agents. The younger the
mice, the faster HCC will develop because of the high hepatocyte proliferation rates of
young animals. Due to the stimulating effect of androgens and the inhibitory effect of
estrogens on hepatocarcinogenesis, HCC deveolps in males more than females [13, 16,
17, 41].
Because of genetic variations between strains, their susceptibility to both
spontaneous and DEN-induced liver cancer are different. CBA and C3H inbred mice
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strains are considered to be highly susceptible to spontaneous incidence of HCC.
While inbred of C57BL/6 and Balb/c mice are relatively resistant to spontaneous
incidence of HCC but relatively sensitive to DEN induced HCC (Table 1) [42].
Carcinogenesis in mice develops in three steps: initiation, promotion, and
progression. Based on the dose of muliple DEN adminstration for around 8-16
weeks, development of liver cancer can be determined. For example, doses below 10
mg/kg of body weight only stimulate the initiation of carcinogenesis. Hepatic fibrosis
is produced at 10-20 mg/kg of body weight, while promotion and progression of
carcinogenesis will be developed at doses equal to or above 25–30 mg/kg of body
weight [43].
The dose requiremnet, time and percentage of cancer development vary
among different strains. For examples, C3H⁄HE mice strain at concendtration of 90
mg⁄kg DEN-induced 100% HCC after 45–75 weeks [44]. DEN-induced C57BL6 ⁄J
mice at concentration 5 mg⁄ kg produecd 84% HCC after 40–70 weeks [45]. When
adult mice are injected weekely for a short time with DEN, it leads to a higher
tumour rate in a shorter time (Table 1). Six weeks of intraperitoneal injections (i.p.)
(3 weeks with 75 mg⁄ kg followed by 3 weeks with 100 mg⁄kg) lead to 100% tumour
incidence after 7 months in male mice [46]. Weekly administration of 50 mg⁄kg DEN
to mice leads to 100% pre-neoplastic lesions dvelopment after 8 months [47].
Hepatocarcinogenesis model can be also be obtained by using initiatione/promotion
protocol that will leads to genomic alterations. While DEN is usually the initator,
promoter agents can be phenobarbital, carbon tetrachloride, partial hepatectomy, or a
high fat diet [17].
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Table 1: DEN administration to wild-type male mice strains via i.p. injection.

Wildtype

Dose
Age

repetition

Strain

Dose
concentration
(per body

HCC
development

References

weight)

Balb/c

15 days

Single

25 or 50 µglg

6- 10 months

[48]

Balb/c

15 days

Single

10 µglg

8 months

[49]

5months
Multiple;
Balb/c

5 weeks

Each dose
Once/week
for 3weeks

75mg/kg
followed by
100mg/kg

(preneoplastic
lesions )

[46]

7 monthsHCC

C57BL/6

15 days

C57BL/6 4 weeks

single

Once/week
for 8 weeks

25mg/kg

8months

[50]

6 months
50mg/kg

( preneoplastic
lesions )

[47]
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HCC development using DEN model is a multistep process, where DEN
works as a complete carcinogen to induce HCC and cycles of de-generation and regeneration activate pre-neoplastic transformations. The progression of early
dysplastic lesions to malignant tumors is associated with an increased occurrence of
genomic alterations. Such genomic alterations are very similar to those associated
with HCC development in humans. Thus, DEN model is consider one of the best
models used to study HCC pathogenesis mechanism in human [17, 51].
1.3.1.2. The aflatoxin model
The aflatoxin B1 is hepatotoxin produced by particular fungi of the
Aspergillus

genus,

for

example

Asparagillus

flavum

and

Aspergillus

parasiticus which are widespread in nature. There are four of aflatoxin (B1, B2, G1
and G2) known to be carcinogenic to both humans and animals. Aflatoxin B1 is the
most potent hepatocarcinogenic of those agents. The Aflatoxin B1 is found in food,
such as corn, rice, oil seeds, dried fruits and peanuts, that have been stored in hot,
humid and inappropriate conditions. It is found in the milk, meat and eggs of farm
animals that feed on contaminated foods with aflatoxin [16, 17, 52, 53].
CYP450 is necessary for the metabolic activity of aflatoxin B1 causing sister
chromatide exchange, chromosomal strand breaks, DNA-adducts, and uncontrolled
DNA synthesis [16, 17, 52, 53].
1.3.1.3. Carbon tetrachloride
Another potent hepatotoxin is carbon tetrachloride (CCl4). The hepatotoxicity
of CCl4 is exerted in several different ways. CCl4 damages hepatocytes directly by
altering the permeability of the plasma, lysosomal, and mitochondrial membranes.
CCl4 is metabolized by CYP2E1, CYP2B1 or CYP2B2 to form trichloromethyl
radicals. These radicals are highly reactive and can bind to cellular molecules, such

16

as nucleic acid, protein and lipid impairing vital cellular processes such as lipid
metabolism, with the result of fatty degeneration (steatosis). Adduct formation
between CCl4 and DNA lead to hepatic cancer [16, 17, 54, 55].
1.3.1.4. Choline deficient diet
Several studies reported that mice subjected to choline deficient diet could
develop HCC in 13 months post 3 weeks continous adminstration of the diet [56].
Abnormal proliferation of oval cells has been proposed as the mechanism through
which

carcinogenicity by choline deficient diet was developed. The abnormal

proliferation of oval cells was a result of ROS generation and oxidative DNA
damage and chromosomal instability because of the depletion of hepatic antioxidant
mechanisms [16, 17].
1.3.2. Xenograft models
Xenograft tumours is one of the most widely used models to study HCC. In
this model, human cancer cells are injected into immune deficient micesuch as
athymic (nude) or severe combined immune deficient (SCID) mice. Depending on
the number of HCC cells injected, the cancer will take to develop around 1–8 weeks.
There are several types of xenograft models including: (1) The ectopic model, in
which human cancer cells are injected subcutaneously in the flanks of mice. (2) The
orthotopic model, in which tumour cells are injected directly into the mice liver. (3)
Hollow fibre assay, in which different cells from different cancer cell lines placed
into small indivial semi-permeable tubes [13, 16, 17, 57]. The advantages of
xenograft models are the rapid tumor grwoth and development. These models also
allow investigation of in vivo toxicity, absorption and pharmacokinetics of the
compounds/drugs. However, the pathological events of tumor development in these
models do not mimic that occur in humans [16, 17].
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1.3.3. Genetically modified models
Genetically modified animals are engineered to resemble pathophysiological
and molecular features of HCC. The genetic profile of these mice is changed, in a
way that one or several genes that involved in the molecular stages leading to the
cancer are mutated, deleted or overexpressed. Genetically modified animals enable
detailed investigation of carcinogenic pathways, exmanine the effect of the modified
genes alone or in combination with carcinogenic agents, and the therapeutic
responses [13, 16, 17, 57].
There are large numbers of HCC transgenic mice, including transgenic mice
over-expressing oncogenes like Myc protein (a transcription factor that upon
mutation it forces cells to proliferate continuously and prevent apoptosis), and mice
over-expressing growth factors, such as Epidermal growth factor that regulate cell
growth, proliferation and differentiation [17, 58].
Because the existing treatments for HCC are not efficient, new treatment
sources are needed to prevent the progress of HCC and deterioration of liver
functions. Many investigations are being carried out worldwide to discover naturally
occurring compounds which can suppress or prevent the development of liver
carcinogenesis. It is well known that many anticancer drugs derived from plants
include Taxol (mitotic inhibitor) from Pacific Yew tree, Vinblastine (antimicrotubule drug)

from Catharanthus roseus, and Campothecin (inhibits DNA

topoisomerase I) from Camptotheca acuminate. The current research suggests that
many herbs and spices contain chemicals that may decrease the incidence of cancer
[59, 60].
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1.4. Saffron
Saffron is world’s most expensive spice that has been widely used as an
herbal medicine, spice, food colouring, and a flavouring agent since ancient times
because of its distinct colour, odor, and taste. It is obtained from the dried stigma
derived from the flower of the plant Crocus sativus Linnaeus (C. sativus L.) [60-63].
The genus Crocus contains around 88 species among which C. sativus L. is the most
investigated species. This herb is cultivated in many different countries, such as
Spain, Kashmir, and Nepal [60-62, 64]. However, Iran accounts for 70% of saffron
worldwide [65].
C. sativus L. grows under hot and dry weather in the summer, but its
vegetative growth is during cold winter. The seeding of saffron takes place in the
months of June and July, while harvesting is end of October-beginning of November.
Saffron can tolerates tempertaure of maximum 45ºC and minimum of -18º C. The
plant is proliferating by bulbs, which divides to yield new plants, and each bulb
produces one to seven flowers [65].
C. sativus L. produces flowers once a year and the flower has three stigmas
(Figure 2). The flowers should be collected immediately because the stigmas might
lose their colour and their volatile aroma components might evaporate. Once the
flowers are gathered, stigmas are removed from the rest of the flowers. The stigmas
and their flowers must be hand-picked because they are delicate [60-62, 64].
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Figure 2: Each flower of C. sativus L. has three stigmas [66].
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More than 85,000 flowers needed to produce only one kilogram (kg) of
stigmas. It is necessary to dry (roasting process) stigmas well for good preservation,
because they have a high level of moisture. After the roasting, 1 kg of raw stigmas
will obtain nearly 200 gram (g) of saffron [60, 62, 63, 66, 67].
While saffron can tolerate high temperatures, it easily degrades in the
presence of light and oxidizing agents. Usually the best saffron sold as whole stigmas
(not powdered) in airtight containers away from light sources to maintain its
integrity. The limited production yield, time and difficult seeding and harvesting
procedures that should be done by hand, these reasons make saffron expensive,
around $40–50 per g [60, 62, 63, 66, 67].
Chemical analysis has shown the presence of estimated 150 volatile and nonvolatile compounds in saffron. It has also some carbohydrates like starch, vitamins,
amino acids, and fats. Saffron’s major components are as the following:
1) Crocin (Di-glycosyl polyene esters of crocetin, hydro-soluble) is responsible
for 80% of saffron colour.
2) Crocetin (Dicarboxylic acid precursor of crocin, lipo-soluble) is also
responsible for 20% of saffron colour.
3) Picrocrocin (Monoterpene glycoside precursor of safranal) is responsible for
the bitter taste. It is the second most abundant component in saffron.
4) Safranal (De-glycosylated form of picrocrocin) is an aromatic aldehyde that
is responsible for saffron volatile oil’s odor.
Dehydration process is not only critical for the preservation of saffron, but is
important for the release of safranal from picrocrocin via enzymatic activity. Then
the reaction produces D-glucose and safranal [62]. Recent studies showed that
saffron has many medicinal properties including anti-oxidants, anti-tumorigenic [68],
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memory enhancer, anti-depressant and cardio-protective agent [60, 62, 67]. As a
major component of saffron, crocin is a main contributing active ingredient to
saffron’s bioactivity. Thus, the following section will focus on crocin.
1.5. Crocin
Crocin is one of the few water-soluble carotenoids found in nature; therefore,
it has various applications as a food colorant and medicinal properties. It is
the diester formed from the disaccharide gentiobiose and the dicarboxylic acid of
crocetin. Gentiobiose is a disaccharide composed of two units of D-glucose, and due
to these sugar moieties crocin has high water solubility [67, 69]. Crocin has a deep
red colour, quickly dissolves in water to form an orange to yellow colour. Crocin
chemical formula is C44H64O24 (Figure 3), with molecular weight is 976.96 g/mol.
The recommended storage temperature is 2-8 °C, and it is light sensitive. It forms
crystals with a melting point of 186 °C. In addition to crocin water solubility, it is
also soluble in methanol and ethanol. [60, 62, 67].
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Figure 3: Schematic representation of crocin chemical structure [67].
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1.5.1. Crocin metabolism
Orally administered crocin hydrolyzed into crocetin before circulated into the
blood, after a single dose or repeated doses for six days of 40mg/kg crocin into rats
and mice. Crocin hydrolyzed into crocetin before or during intestinal absorption.
Crocetin was then partly metabolized into mono- and di-glucuronide conjugates. The
plasma concentration of crocetin was decreasing, after 1 hr of single oral dose of
crocin. This indicates that crocetin might rapidly be eliminated without accumulation
in the body. This is consistent with the short plasma half-life of crocetin [70-72]
Crocin as intact form was largely present in feces and intestinal contents, but
not in the urine post 24 hrs of administration. The amount of crocin lost in the colon
was greater than other parts of intestine (Duodenum, Jejunum and Ileum), that
probably because of higher basic condition within the colon. Consequently, the
intestinal tract serves as an important site for crocin hydrolysis [70, 71]. However,
another study reported that crocin could be excreted by the urine after long term
exposure, 21 days, of 180mg/kg crocin i.p. administrated (Hosseinzadeh, Shariaty,
Sameni, & Vahabzadeh, 2010.
1.5.2. Crocin sources
Crocin found to be the main pigment of the saffron as mentioned earlier. The
amount of crocin in saffron is varying depending on the growing conditions, drying
processes, duration and storage methods. Greek and Kashmiri saffron have the
highest concentration of crocin followed by India and New Zealand [67, 69]. In
addition, crocin obtained from the fruits and flowers of gardenia, in specific
Gardenia jasminoides Ellis species. This species has traditionally used as a folk
medicine in few Asian countries like china, Japan, India and Pakistan. This species is
less common compared to C. sativus L. [73].
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1.5.3. Biological activities of crocin
Many beneficial effects of crocin against different illnesses have been
reported inclduing being a potent anti-cardiovascular, anti-cancer, anti-oxidant, antiinflammatory, and anti-depressant and as a promoting agent of learning and memory
[67].
1.5.3.1. Anticancer effect
Several studies have shown that the crocin can inhibit the growth of different
types of cancers such as leukaemia, osteosarcoma, fibrosarcoma and ovarian
carcinoma and breast cells. Crocin decreased MCF-7 and Hela cell lines by downregulating the expression of Bcl-2, and up-regulating the expression of Bax. Crocin
induced apoptosis and G1 cell cycle arrest in human pancreatic and tongue squamous
cancer cell lines [67]. It was also reported that crocin inhibit the proliferation of three
colorectal cell lines (HCT-116, SW- 480, and HT-29) and human non-small cell lung
cancer (NSCLC) cells. On the other hand, no toxic effect was reported on normal
cells, non-cancer young adult mouse colon (YAMC) cells [74].
Crocin also reduced the formation of mouse skin papillomas when they were
injected subcutaneously with 85 nmol of crocin [75]. The life span of rats was
increased and colon tumor growth was decreased in female rats without showing any
significant toxic effects, after long-term treatment of crocin. The treatment was
weekly for 13 weeks with subcutaneous administration of crocin 400mg/kg [76].
1.5.3.2. Effect on gastric disorders
Several studies reported that crocin decreased the gastric diseases. Kianbakht
et al. have shown that orally administrated of crocin at 10mg/kg reduced ulcer
formation, due to it is antioxidant properties. Crocin prevented indomethacin-induced
gastric mucosa damage by increasing glutathione levels and preventing lipid
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oxidation [77]. A similar study tested the capability of crocin to prevent stomach
lesions in rats treated with indomethacin, an anti-inflammatory drug known to cause
ulcers. The results showed that crocin protected the stomach mucosa from damage
compared to un-treated group [78]. These studies also emphasized the safety of
crocin since the rats did not display gastric ulceration at the highest crocin doses of
10 mg/kg or 50 mg/kg in normal tested animals [77, 78].
1.5.3.3. Antioxidant effect
As a potential radical scavenging agent, crocin is a potent neuro-protective,
anti-aging, anti-inflammatory, and anti-cancer biomolecule. Bors et al. in 1982 was
the first to report the anit-oxidant activity of crocin [79]. The anti-oxidant
mechanisms of crocin are mainly attributed to its scavenging ability of superoxide
anions and nitrite, 2,20-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) radical
cations inhibition, superoxide dismutase-like activity and the reduction of
intracellular ROS production [80].
Santhosh et al. studied the role of crocin in treating the secondary
complications of snakebite. Rats treated i.p. with venom mixed crocin. The results
indicated that in crocin reduced the level of pro-inflammatory cytokines, such as IL1ß, IL-6, and TNF-α, and decreased the oxidative stress induced by venom [81]. The
protective role of crocin against beryllium chloride toxicity in rats was investigated
at a dose of 200mg/kg i.p. treatment for 7 days prior to beryllium chloride intake
resulted in significant reduction in beryllium chloride-induced oxidative stress,
combined with initiation of mRNA expression of catalase and superoxide dismutase
genes. The hematological and biochemical parameters such as lactate dehydrogenase
levels were restored near the normal levels [82].
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1.5.3.4. Anti-inflammation effect
Recent studies revealed that crocin exerts anti-inflammatory and antinociceptive activities. Tamaddonfard et al. tested the effects of i.p. treatment of
crocin at doses of 25, 50, and 100 mg/kg on local inflammation and inflammatory
pain responses induced by intra-plantar injection of carrageenan in rats. The results
showed anti-inflammatory and anti-nociceptive activities of crocin in a dose
dependent manner by decreasing the inflammatory pain responses and number of
neutrophils in carrageenan model [83].
A study by Xu et al. evaluated the anti-inflammatory effects of crocin in vitro
and in vivo. In vitro, cyclooxygenase inhibition assays showed that crocin
concentrations (0.01, 0.1, 1.0, 10, 30, and 100 μM) displayed a dual inhibitory
activity against the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2)
enzymes in lipopolysaccharide-challenged RAW 264.7 murine macrophages cells in
a dose dependent manner. Crocin also suppressed the productions of prostaglandin
E2 [78]. Anti-inflammatory activity in vivo examined using two animal edema model
tests. Pre-treatment with crocin at doses 12, 25, and 50mg/kg were administered
orally, inhibited the xylene-induced ear edema in mice and carrageenan-induced paw
edema in rats in a dose dependent manner. These results indicated that crocin
exhibits obvious anti-inflammatory effects [78].
1.5.4. Safety of crocin
Several studies conducted by researchers to investigate the potential safety of
crocin. Wang et al. reported that crocin caused reversible and dose dependent black
pigmentation of the liver, and acute hepatic damage related to discoloration. In rats
orally administered with crocin daily at dose of 50 mg/kg for 8 days, the liver
function was normal. However, higher daily dosage of 100 mg/kg for longer
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duration, 2 weeks, induced reversible hepatic damage and black pigmentation. These
results suggested that the crocin has low toxicity in rats even in high experimental
dosage, which would hardly happen in human practice; therefore, crocin is safe for
human consumption [84].
Hosseinzadeh et al. reported a more comprehensive study in 2010 to
investigate biochemical, hematological and pathological toxic effect of crocin in
mice and rats in major organs, like heart, liver, lung, spleen, and kidney. The acute
toxicity studied at doses 3 g/kg given orally and i.p. once a day for 2 days, and the
sub-acute toxicity at doses 15, 45, 90 and 180 mg/kg, i.p. daily for 21 days
(Hosseinzadeh, Shariaty, Sameni, & Vahabzadeh, 2010). Oral and i.p. doses of 3
g/kg crocin did not cause any pathological changes and death within 2 days of study.
However, there was a reduction in appetite, weight, and in alveolar size in lungs only
at 180 mg/kg group compared to control group. Regardless the excessive loss of
crocin in 180 mg/kg group that made the urine orange-yellow color, there was no
pathologic change in kidney. The results obtained indicated that crocin at
pharmacological doses less than 180 mg/kg did not cause damage to all the major
organs of the body, and it might has low toxicity at 180mg/kg post long time
administration [85].
In 2013, crocin tablets 20mg/day for 4 weeks were evaluated by
Mohamadpour et al., for short-term safety and tolerability in healthy adult male and
female volunteers. General health measures recorded before, after and during the
study, such as hematological, biochemical, hormonal and urinary parameters. The
results of this clinical safety evaluation showed a relatively safe and normal profile
for crocin in healthy volunteers at the given doses within the trial period [86]. In
addition, saffron as a whole extract has a high LD50=20 g/kg, that is why recently
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toxicology researchers consider it to be safe for human intake. The amount used in
daily food consumption is actually much lower than the dose causing any of the
reported side effects [62].
Attaching or conjugating crocin on delivery systems like nanoparticles (NPs)
can improve the therapeutic effects of crocin as anticancer agent. Crocin-conjugated
NPs may offer several advantages including: (1) Prolonging crocin circulation time.
(2) Preserving crocin as intact form not to convert to crocetin. (3) Reducing the
crocin doses concentration. (4) Specific delivering to cancer site, due to passive
targeting that lead to increase accumulation of crocin in cancer tissue, because of
their leaky microvessels and the lack of efficient lymphatic drainage that do not exist
in normal tissue.
1.6. Nanoparticles (NPs)
Nanotechnology is a multidisciplinary branch of science, which is
dynamically growing field of both academic and industrial interest. In this branch
advanced materials are used for various applications such as biomedical,
pharmaceutical, agricultural, environmental, and comprised different fields of
science, engineering and medicine. As a result of rapid development in these fields,
there is a significant increase in the development of novel nanomaterials [87-89]. The
prefix ‘nano’ derives from the Greek meaning ‘dwarf’. The European Committee for
Standardization defines nanomaterials as materials with an external dimension at the
nanoscale, or that have nanoscale internal or surface structures. Nanoscale describes
the size range from approximately 1 to 100 nm (ISO/TS 27687:2008) [88].
Various structures of nanomaterials were produced and applied such as NPs,
nanocapsules, nanotubes, and nanofibers. NPs are the one of the most widely studied
and used nanomaterials. NPs can be spherical, tubular, or irregularly shaped, and can
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occur in the form of fused or agglomerated forms. NPs can be divided into two main
types; natural and engineered. Natural NPs present in the environment result from
events such as terrestrial dust storms, erosion, and volcanic eruptions that happened
naturally. While, engineered NPs were manufactured by human using different
materials. These materials, including metals (Ag, Zn, Au, Ni, Fe, and Cu), metal
oxides (TiO2, Fe3O4, SiO2, and Al2O3), non-metals (silica and quantum dots), carbon
(nanotubes),

polymers

(alginate,

chitosan,

hydroxymethylcellulose,

and

polycaprolactone), and lipids (soybean lecithin and stearic acid) [88, 89]. Some of
the nanomaterials approved by Food and Drug Administration (FDA) and
commercialized for biomedical applications, especially for the treatment of cancer,
are listed in Table 2 [90, 91]. Many engineered NPs have been developed for
biomedical applications.
Superparamagnetic iron-oxide NPs (SPIONs) are among the different types
of Engineered NPs, that are considered to be promising candidates in cancer
therapeutic and diagnostic (theranostics) applications due to their unique properties.
These properties include superparamagnetic behaviour, biocompatibility, flexible
surface-modification, and high surface to volume ratio by virtue of their small size.
These kinds of NPs are also biodegradable, because they can be metabolized,
transported, and stored in proteins like ferritin, transferritin and hemosiderin [92, 93].
Due to their unique features, SPIONs have various applications in
biomedical fields such as magnetic separation, biosensing, gene therapy, detection of
biological entities like cells and proteins, and tissue repair. Moreover, SPIONs were
investigated in the area of cancer therapeutics, where they were found to have a
potential in improving the contrasting features in MRI, biological labelling, drug
delivery, and hyperthermia. Recently, several SPIONs formulations have been

30

approved for clinical use, for MRI as contrast agents and therapeutic purposes, such
as: Lumiren for bowel imaging, Feridex IV for liver and spleen imaging, Combidex
for lymph node metastases imaging, and Ferumoxytol for iron replacement therapy
[93-95].
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Table 2: Some of the approved or marketed nanomaterials for cancer treatment.

Name

Nanomaterial/
active agent

Cancer

Status

Doxil/Caelyx
1

PEGylated
liposome/doxorubicin
hydrochloride

Ovarian
cancer

Approved
11/17/1995
FDA50718

Myocet

Non-PEGylated
liposomal doxorubicin
nanomedicine

Metastatic
breast cancer

Approved in
Europe and
Canada, in
combination with
cyclophosphamide

DaunoXome

Liposomal
daunorubicin

ThermoDox

Heat-activated
liposomal
encapsulation of
doxorubicin

First-line
treatment for
patients with
advanced
HIVassociated
Kaposi’s
sarcoma
Breast
cancer,
primary liver
cancer

Abraxane

Paclitaxel albumin
nanoparticle

Rexin-G

Targeting protein
tagged
phospholipid/microRN
A- 122 (Targeted gene
Therapy)

Company/
Reference
Ortho
Biotech
(acquired by
JNJ)
Sopherion
erapeutics,
LLC in
North
America and
Cephalon,
Inc. in
Europe

Approved in the
USA

Galen Ltd.

Approved

Celsion

Various
cancers

Approved
1/7/2005
FDA21660

Celgene

Sarcoma,
osteosarcom
a, pancreatic
cancer, and
other solid
tumour

Phase II/III,
approved in
Philippines

Epeius
Biotechnolo
gies Corp.
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The concept of using magnetic NPs for drug delivery was proposed in the late
1970s by Widder and his colleagues [96, 97]. However, the idea of using magnetic
NPs as a carrier that can be targeted to a certain site using external magnetic field
date back to early 1940s, as a new methodology in waste water treatment [98].
Magnetite is among the most commonly studied SPIONs [87, 99].
1.7.

Magnetite nanoparticles (MNPs)
MNPs are one of the most attractive used SPIONs in cancer therapy and other

biomedical applications, due to their chemical stability, biodegradability, reactive
surface that can be modified, and magnetic properties [89, 92-94]. Magnetite (MN)
with a chemical formula Fe3O4 is a mineral and one of the three naturally
occurring iron oxides (maghemite; γ-Fe2O3, and hematite; α-Fe2O3) [92]. MN is
considered the most magnetic of all the naturally occurring minerals on Earth [100].
MN is black or brownish-black with molecular weight of 231.55 g/mol. It has
a density of 5.18 g/cm3, a melting point of 1583-1597 °C, and a hardness of 5-6 on
Mohs scale of mineral hardness. The chemical name of MN according to
International Union of Pure and Applied Chemistry (IUPAC) is iron (II,III)
oxide, and the common name is ferrous-ferric oxide. The chemical formula of MN
can also be written as FeO·Fe2O3 [100-103]. MNPs have been widely investigated in
the last decades for a wide range of applications. In biomedical applications, they
have been studied as MRI contrast agent, immunoassay, detoxification of biological
fluids, hyperthermia, cell separation, and drug delivery [87, 99, 104].
To be used in biomedical applications, the composition, size, charge, and
surface chemistry of the MNPs are important and strongly affect both the blood
circulation time as well as bioavailability of these nanoparticles within the body. In
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addition, magnetic properties and internalization process of MNPs depend strongly
on their size [94].
For the systemic administration, smaller particles with diameters of smaller
than 10 nm can be rapidly removed by renal clearance. On the other hand, particles
with diameters bigger than 100-200 nm are usually sequestered by the spleen and
liver as a result of mechanical filtration and are eventually removed by the cells of
the phagocyte system, resulting in decreased blood circulation times. NPs in the
range of 10-100 nm are optimal, safe, and demonstrate the most prolonged blood
circulation times. Most endothelial barriers allow MNPs less than 150 nm to pass,
more stringent barriers, such as the blood brain barrier allow 15 to 50 nm to pass
with molecular weight smaller than 500 Da [92, 94, 105-107] [102, 108].
1.7.1. MNPs Crystal structure
MN has a cubic inverse spinel structure. The large oxygen ions form a closepacked cubic lattice, with the Fe ions filling the gap between them. The iron ions in
the gaps arranged in two different sites: (1) Tetrahedral site: Fe ion is surrounded by
four oxygens, and form a magnetic sublattice. These sites are exclusively occupied
by the smaller ferric iron Fe3+ atoms. (2) Octahedral site: Fe ion is surrounded by six
oxygens, and form B magnetic sublattices. These sites are randomly occupied by
subequal numbers of ferric (Fe3+) and ferrous (Fe2+) iron atoms.
The spins on the A sublattice are antiparallel to those on the B sublattice. The
two crystal sites are very different and result in complex forms of exchange
interactions of the iron ions between and within the two types of sites. MN exhibits a
variety of characteristics that depend on the temperature [100, 109].
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1.7.2. Superparamagnetism property of MNPs
MN is a ferrimagnetic material at room temperature, with populations of
atoms with opposite direction of magnetic moments. Ferrimagnetic materials can be
magnetized by an external magnetic field and remain magnetized after removing the
external field. MN has a Curie temperature of 850 K (577ºC), which is temperature
where a material's permanent magnetism changes to induced magnetism [110].
MNPs are also known as superparamagnetic; SPIONs. The term superparamagnetism
refers to a specific NPs size of 1– 30 nm [111]. In other studies the size is smaller
than 10 nm at room temperature [103]. Goya et al. investigated the magnetic
properties of MNPs of size between 5 and 150 nm and he concluded that the
magnetization was increased as the particle size decreased [112].
The bulk of MNPs contains multiple domains and expresses ferromagnetic
behaviour. The material with a higher number of domains produces less internal
energy, and vice versa. As the size of the particles decrease to less than 30 nm, the
number of domains decreases to be single domain. In such a state of
superparamagnetic behaviour, the MNPs show ferromagnetic or paramagnetic
properties, according the presence or absence of external magnetic field, receptively.
Paramagnetism is the type of magnetism that occurs only in the presence of an
externally applied magnetic field [93, 111].
When an external magnetic field is applied, the single-domain of MNPs
aligns all their magnetic moments in the same direction as this external magnetic
field, resulting in a high magnetization (Figure 4). Due to the superparamagnetic
behaviour of MNPs, they have been used as MRI contrast agents in diagnosis, as heat
mediators in hyperthermia treatments and additionally as magnetic guidance in drug
delivery applications [101, 103, 111].
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MNPs magnetic properties strongly depend on the methods used in their
synthesis. Moreover, Teja et al. reported that the magnetic properties of MNPs
appeared to depend strongly on changes in the crystal morphology. The crystal
morphology affects coercivity in the order: spheres < cubes < octahedra in line with
the increase in the number of magnetic axes along this series of shapes. Coercivity is
the intensity of the applied magnetic field required to reduce the magnetization of
that material to zero after the magnetization of the sample has been driven to
saturation. MNPs with coercivities ranging from 2.4 to 20 kA/m have been produced
by controlling their synthesis conditions [101, 103].
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Figure 4: Diagrammatic representation of the behaviour of multiple domains of a
ferromagnetic material, and the single-domain of superparamagnetic MNPs in the
presence or absence of external magnetic field, modified from [113].
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1.7.3. Synthesis of MNPs
Considering the increasing number of potential applications for MNPs, it is not
surprising that various synthetic routes have been described with different abilities to
control the size and size distribution, shape, polydispersity, surface charge, magnetic
susceptibility, crystallinity, surface chemistry and the yield of production. These
methods

include:

wet

or

co-precipitation,

hydrothermal

reactions,

thermal

decomposition, microemulsions, sol-gel syntheses, sonochemical reactions, hydrolysis
and thermolysis of precursors, flow injection syntheses and others [102, 103, 107, 111].
Some of these methods are described in the following sections.
1.7.3.1.

Co-precipitation method
Co-precipitation is a method where Fe2+ and Fe3+ salts co-precipitate in the

presence of an alkaline aqueous media. It is the simplest, the most common, most
efficient, and universally used chemical pathway to obtain MNPs. The precipitated
MNPs are dark or brownish-black in colour. The chemical reaction describing
precipitation of Fe3O4 is given in the following equation:
Fe2+ + 2Fe3+ + 8OH-  Fe3O4 + 4H2O

Equation 1

According to the thermodynamics of this reaction, a complete precipitation of
MNPs should be expected at a pH between 8 and 14 where the precipitated MNPs
acquire negative charges on their surfaces, while maintaining a stoichiometric ratio of
2:1 (Fe3+/Fe2+) under a non-oxidizing environment. Otherwise, MNPs might also be
oxidized to other impure phases like maghemite. Oxidation in air is not the only way to
transform magnetite into maghemite (γ-Fe2O3). Various electron or ion transfer
incidents, depending upon the pH of the suspension, are involved, according to the
following equation:
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Fe3O4+ 2H+  γ-Fe2O3+Fe2+ + H2O

Equation 2

This would critically affect the physical and chemical properties of the MNPs. Bubbling
nitrogen gas through the solution not only prevents critical oxidation of magnetite, but
also reduces the particle size when compared to methods that use an oxygenated
environment [114-117].
The size, monodispersity, and shape of MNPs can be tailored or adjusted by a
number of factors, such as pH, addition of alkaline solution before or after the addition
of Fe2+/Fe3+ ions solution, altering the feeding rate of the iron ions solution, ionic
strength of Fe2+ and Fe3+, stirring and soaking temperatures, nature of the iron salts, and
addition of the coating layers before, during or after MNPs synthesis [111, 114, 116118]. Despite the above mentioned advantages of the co-precipitation method, few
disadvantages may arise due to experimental parameters variation, such as large
particles of varying diameters, polydispersity, and poor crystallization. These
disadvantages can be overcome by monitoring the previous mentioned factors [93, 102].
Several studies explored the preparation of MNPs in an oxygen-free atmosphere. For
example, Iwasaki et al. prepared MNPs to test the effect of pressure on their size. These
NPs synthesized using the co-precipitation method by adding alkaline solution to ferric
and ferrous ions in an argon atmosphere. After that, a cooled ball mill was used as a
synthesis reaction medium in which MNPs of about 10 nm were prepared by
mechanochemical effect without heating the starting suspension and annealing the
product [119].
Yazdani et al. sealed the reaction vessel after being filled with iron ions then
injected with an alkaline solution, following which different pressures of nitrogen gas
were applied. By increasing the nitrogen reaction pressure from 300 to 6000 mbar, the
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particle size increased from 8.3 to 16.8 nm at 25°C [120]. In addition, Sun et al.
synthesized MNPs with a size range of 8-20 nm using a modified, chemically controlled
co-precipitation method. Sodium oleate, as surfactant, was added during the reaction to
enhance the compatibility of the nanoparticles [121].
1.7.3.2. Hydrothermal method
A hydrothermal process was used to produce MNPs due to its advantages in
producing high yield of NPs with excellent crystallinity and controllable size and
morphology. Furthermore organic reagents are not needed, so this method is
comparatively environmentally benign, and is relatively cost-effective [116]. In this
method, synthesis of MNPs is usually carried out by precipitating ferrous and ferric ions
in an alkaline medium with a molar ratio 1:2 similar to the co-precipitation method.
Dilute acid is also added to avoid the precipitation of other iron oxides before the
addition of alkaline solution. The mixture is then added into a nitrogen gas blanketed
three neck flask and stirred at a constant rate for a short time. After that, the precipitated
black product is immediately added into a Teflon-lined stainless steel autoclave and
subsequently placed in a furnace at high temperature (200°C) [116, 122-125].
Control of the particle size and morphology in this hydrothermal method take
place through the processes of nucleation and grain growth. Nucleation might be faster
than grain growth at higher temperatures and results in a decrease in particle size. In
addition, prolonging the reaction time would favour grain growth [116, 122-125].
MNPs with an average particle size of 17.22 nm were obtained at 200°C and
were coated with chitosan to modify their surfaces [122]. Also, MNPs with a diameter of
27 nm were prepared by this method in the presence of a surfactant; sodium bis (2
ethylhexyl) sulfosuccinate [126]. In addition, size control using lactate and sulfate ions
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was investigated by Mizutani et al., who prepared also MNPs in an argon atmosphere
and then autoclaved at 120°C for 20 hr in an electric oven. The median particle size
obtained varied from 9.5 to 38.6 nm. This was found strongly dependent on the stability
of iron complexes and the surface potential of anions-adsorbed precipitates [127].
1.7.3.3. Thermal decomposition
MNPs with a high level of monodispersity and size control were also obtained by
a thermal decomposition procedure. In this method, iron precursors decomposed in hot
organic solvents in the presence of stabilizing surfactants (e.g. oleylamine, oleic acid,
and steric acid) and organic solvents (such as hexane and toluene). Iron precursors
include iron (III) acetylacetonate; Fe(acac)3, iron pentacarbonyl; Fe(CO)5 , and iron (III)
cupferronates; Fe(Cup)3 [114, 128].
Sun et al. have described a high-temperature reaction of Fe(acac)3 with 1,2hexadecanediol in the presence of oleic acid and oleylamine to obtain monodispersed
MNPs. The particle diameter could be tuned from 3 to 20 nm under a flow of nitrogen
gas, and the hydrophobic particles could be transformed into hydrophilic ones by adding
a bipolar surfactant [129-131]. Also, thermal decomposition of Fe(CO)5 in octyl ether
solution of oleic acid with consecutive aeration resulted in MNPs with a narrow size
distribution. [132].
Li et al. and other researchers described the synthesis of water-dispersible MNPs
in acidic or basic media by thermal decomposition of Fe(acac)3 [133-136] or
inexpensive ferric chloride (FeCl3) in refluxing 2-pyrrolidone. The latter is not only a
high boiling solvent but also a stabilizer because of its coordination capacity with metal
ions. According to the reflux time, size could be controlled to obtain MNPs with
diameters of 4, 12 and 60 nm [134].
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1.7.4. Desirable features of MNPs
Using different manufacturing procedures, the desirable features of synthesized
MNPs for biomedical applications, specifically cancer treatment, are: stable at
physiological pH, with high magnetization, size is 10-100 nm in diameter to avoid
elimination from biological system, narrow size distribution, high reactive surface,
biocompatible, biodegradable and able to respond to stimuli, such as magnetic field,
heat, and pH.
However, there are significant issues with naked MNPs that affect and reduce
their efficacy in cancer treatment application, including:
1) They tend to agglomerate and aggregate, because of hydrophobic–hydrophobic
interactions between the MNPs, and magnetic properties with a large surface
area to volume ratio.
2) Because of their agglomeration, they will be rapidly eliminated from the
circulation; hence their half-life will be short.
3) They have low stability and dispersibility.
4) They are toxic, because they circulate inside the body without any specific
interaction with the organs or tissues.
To overcome these issues, the development of a proper surface coating is needed
to improve MNPs efficacy in clinical applications [116, 137-141].
1.7.5. Surface modification of MNPs
The surface coating of MNPs with various coating materials play an important
role in the stabilization of aqueous MNPs suspensions, as well as in their further
functionalization. The surface modifications provide and offer the following advantages
for MNPs [87, 99, 104, 142, 143]:
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1) Reduce the agglomeration.
2) Improve their stability in various solvents to extend their half-life and blood
circulation time in physiological conditions.
3) Control their growth and size.
4) Prevent the oxidation of MNPs.
5) Improve their biocompatibility and reduce toxicity.
6) Limit non-specific cell binding by being targeted.
7) Modify the physical and chemical properties of MNPs, such as electronic,
optical, spectroscopic, and surface charge
8) Provide functional groups for further modification, such as attachment of optical
dyes, therapeutic and targeting agents
9) Reduce of the therapeutic drugs dose quantity.
The stabilization of the MNPs is crucial to obtain magnetic colloidal ferrofluids
that are stable against aggregation in a biological medium and a magnetic field. MNPs
coatings can be comprised of several types of materials, including monomeric stabilizers
such as carboxylates and phosphates, polymeric, non-polymeric like oleic acid, and
stearic acid, liposomes, micelles, and inorganic materials such as silica and gold [87, 89,
94, 102]. These materials together with various surfactants, such as sodium oleate,
dodecylamine and sodium dodecyl sulfate (SDS), are all used to enhance dispersibility
of the NPs in the solution, and they bind differently to their surfaces. Some researchers
explored the use of more than one coating materials (such as co-polymers) to coat MNPs
to perform specific functions. The NPs coating can be achieved via a number of
approaches, including pre-synthesis, in situ coating and post-synthesis [94, 116, 144,
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145]. Table 3 list examples of FDA clinically approved organic-materials coated MNPs
[90, 91, 146].
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Table 3: Examples of FDA clinically approved, commercially available organicmaterials coated MNPs, commonly used as contrast agents in MRI imaging (except
NanoTherm for hyperthermia treatment).
Name (half-life)
Feridex IV/
Endorem
(8-30 minutes)
Resovist/supravis
t
Combidex
(25-30 hrs)
Clariscan
(45–120 minutes)
GastroMARK
(4 -7hrs)
Abdoscan

Feraheme
(15hrs)

NanoTherm
(hyperthermia)

Size
(nm)

Target

Coating type

Status

Company

80-150

Liver/spleen

Dextran

Approved

Berlex
Laboratories

80-150

Liver/spleen

Carboxy-dextran

Approved

15-30

Lymph node
metastases

Dextran

Phase III

20

Tumor
microvasculat
ure

PEG

Discontin
ued due
to safety
concern

Nycomed
Imaging

Bowel

Silicone

Approved

AMAG
Pharma

Approved

Nycomed
Imaging

Phase II

AMAG
Pharma

Approved

MagForce,
Nanotechnol
ogies AG

400

300

Bowel

30

Vasculature

10-20

In situ
injection (e.g.
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1.7.5.1.

Surface modification with polymeric materials
Polymeric coatings prevent the agglomeration of the MNPs and limit their non-

specific cell binding in the biological system. Structural features of the polymeric
coatings may affect the performance of coated MNPs. These include the nature of the
chemical structure of the polymer (such as hydrophobicity and biodegradation
characteristics), the length or molecular weight of the polymer, the type of chemical
bond in which the polymer is attached (for example covalent bonding), the conformation
of the polymer, and the degree of particle surface coverage. Polymeric coating materials
are classified into natural and synthetic. Examples of natural polymers are dextran,
chitosan, starch, and cellulose. The synthetic polymers include polyethylene glycol
(PEG), poly-vinylpyrrolidone and poly-ethyleneimine. Dextran and chitosan are two of
the most commonly used natural and synthetic polymers will be discussed in details in
the following sections [114, 117, 118, 144, 147, 148].
1.7.5.1.1. Dextran
Dextran is a natural branched polysaccharide polymer comprised of glucose
subunits, which can be prepared with sizes ranging from 10 to 150 kDa. Dextran has
been widely used as a polymeric coating mostly because of it is biocompatibility, nontoxicity and polar interactions (chelation and hydrogen bonding) that give dextran a high
affinity towards MNPs surfaces. Dextran bind to MNPs surface by covalent bond
between oxygen and iron II and III ions along the MNPs surfaces [94, 116, 118, 149]. In
1982, Molday and Mackenzie were the first to report the formation of MNPs in the
presence of dextran. They prepared MNPs by a co-precipitation method with in situ
coating by dextran of 40 kDa molecular weight and produced MNPs with 15-30 nm in
diameter. Since then, various forms of dextran polymers, including carboxydextran and
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carboxymethyl dextran were used to coat surfaces of MNPs with varying hydrodynamic
sizes [148, 150, 151].
Other approaches were also explored for applying dextran coating onto MNPs.
Sonvico et al. modified the surfaces of MNPs with amino-propylsilane, followed by
covalent conjugation of partially oxidized dextran via a secondary amine bond. Another
study performed by Woo et al., who modified the hydrophobic surface of MNPs to
hydrophilic via Fe-S covalent bond with bi-functional 3-mercaptopronic acid, and then
the terminal carboxylic acid group was esterified with dextran to improve
biocompatibility [149, 150]. Mykhaylyk et al. also prepared MNPs via precipitation
from iron (II) sulphate aqueous. Then the surface of freshly prepared MNPs were
immediately modified by spontaneous adsorption of dextran from aqueous solution. The
modified MNPs (24 nm in diameter) were able to target rat glial tumors by disrupting
the blood-brain barrier immediately prior to particle injection [137, 152].
1.7.5.1.2. Chitosan
Chitosan is one of the most abundant natural linear poly-aminosaccharide,
hydrophilic, non-toxic, biocompatible, and biodegradable polymer. It has enormous
applications in the pharmaceutical industry, such as drug carrier, absorption
enhancement, gene delivery, and is a metal chelating agent. Chitosan possesses both
amino and hydroxyl functional groups, which can bind with other functional molecules
that are commonly used as targeting, imaging and therapeutic agents (Jana Chomoucka
et al., 2010; Dash, Chiellini, Ottenbrite, & Chiellini, 2011). Chitosan is soluble in acidic
media and is also used as a surfactant agent. Adding chitosan on the surface of the
MNPs will enhance their stability and biocompatibility to be used in different
applications [94, 115, 153-156].
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Several studies have investigated the preparation of chitosan coated MNPs for
different applications. For examples, Tran et al. and Boddu et al. formed chitosan coated
MNPs (C-MNPs) to remove metal ions pollutants from aqueous solution [157-159]. CMNPs were prepared by co-precipitation of MNPs in the presence of chitosan followed
by hydrothermal treatment. Another study used C-MNPs as MRI contrast agent, which
can be used for cell tracking, cancer detection and therapeutically response assessment
[122, 160-162]. Similarly, Kim et al. synthesized MNPs by sonochemical method. From
these MNPs, they synthesized ferrofluids for use as MRI contrast agents by coating them
with oleic acid as a cross-linker and then dispersing them in chitosan, yielding
spherically shaped MNPs with 15 nm in diameter [94, 163]. In a study carried out by Qu
et al. C-MNPs with core-shell structure with 11 nm in diameter have been prepared
using cross-linking method. Oleic acid modified MNPs were firstly prepared and then
chitosan was added to coat the surface of the MNPs by physical absorption. The CMNPs were obtained by cross-linking the amino groups on the chitosan using
glutaraldehyde (cross-linker) [155, 161, 164].
1.7.5.2.

Surfactant coating material

1.7.5.2.1. SDS
SDS is one of the most used anionic alkyl sulfate surfactants. SDS synthesis is a
relatively simple procedure involving the sulfation of 1-dodecanol followed by
neutralization with a cation source. Because of its high reactive surface properties, it is
important in industrial cleaners, and cosmetics. In addition, it has been used in different
kinds of industrial manufacturing procedures, as a delivery aid in pharmaceuticals, and
in biochemical research [165, 166]. In the physiological system, SDS can enhance
absorption of chemicals through skin, gastrointestinal mucosa, and other mucous
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membranes. SDS is known for its fast uptake, distribution, and excretion. It accumulates
selectively in the hepatopancreas and gall bladder, and gets absorbed via the intestine,
colon, and skin. Metabolism procedure of SDS takes place by proceeding from initial
omega-oxidation to a carboxylic acid, then to beta-oxidation to butyric acid 4-sulfate,
which is finally non-enzymatically de-sulfurated to gamma-butyrolactone and inorganic
sulfate. SDS stimulates both physical and biochemical effects on cells, and specifically
targets the membrane [165].
Shariati et al. investigated the ability of S-MNPs to efficiency remove the
safranin O dye from waste water. In this study, MNPs were synthesized via coprecipitation method in the presence of SDS to the mixture solutions of iron ions. The
effects of various parameters on the removal efficiency of dye, such as the type and
amount of surfactant, pH of solution, salt effect, and contact time were studied and
optimized. The results suggested that S-MNPs with size less than 40 nm can be used as
an efficient adsorbent material for adsorption of cationic dyes from aqueous solutions
with high removal at acidic media pH 2 [166]. On the other hand, S-MNPs were
synthesized by Adeli et al. using a co-precipitation method. S-MNPs prepared herewith
were applied for the removal and recovery of copper, nickel and zinc from industrial
waste water due to high concentration of these metal ions in the real samples. The
obtained results reported that S-MNPs were efficient adsorbent material for removal of
the metal ions from wastewater samples [167].
1.7.6. Surface functionalization of MNPs
The modified surfaces of the MNPs not only stabilize the magnetic core, but they
can also provide functional groups for further modification. Those functional groups can
bind to different molecules, such as targeting agents, optical dyes, therapeutic agents,
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enzymes, and nucleic acids. When the MNPs functionalized with more than one type of
molecule, they are termed multifunctional. These molecules can be conjugated on the
surface or incorporated within MNPs. They also can bind to the modified surface by
chemical bonds or by avidin-biotin protein coupling technique. These chemical bonds
include amide, ester, hydrogen and other bonds. The functionalization of MNPs surface
is a method for tuning the overall properties of particles to fit targeted applications [87,
92-94].
Surface modification of MNPs using functional molecules has different tasks to
fulfil, such as:
1) Improve the mechanical and chemical performance of the modified surface of the
MNPs.
2) Improve the effect of anti-cancer drugs/bioactive molecules.
3) Target desired chemical, physical, or biological environments.
In the current study, crocin has been selected to be added to the surface of
dextran coated MNPs. It was found that among several new drug delivery systems,
functionalized MNPs have emerged as a promising technology to deliver crocin to their
site of actions. By reducing the uptake of crocin by phagocytic cells, prolonging crocin
circulation time, preserving crocin as intact form and passively accumulate in the tumour
location, leading to improve the therapeutic effect of crocin versus free crocin [87, 9294].
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1.8. Aims of the study
Crocin has been shown to have the potential of inhibiting tumorigenesis in a
variety of cancers including hepatocellular carcinoma. Among several drug delivery
systems, MNPs coated with natural polymers like dextran have emerged as a promising
technology to deliver biomolecules to their target site of actions. Coated MNPs can
improve the therapeutic effects of crocin as anti-cancer agents versus free crocin because
of several reasons. These reasons include that coated MNPs can reduce the uptake by
phagocytic cells, prolong the circulation time, and passively accumulate in the cancer
areas due to the leaky microvasculature and the lack of efficient lymphatic drainage in
those sites.
The main objective of the present study was set to mainly assess the anti-cancer
effect of crocin-loaded NPs both in vitro and in vivo.
The detailed objectives are:
1. To prepare and characterize MNPs with uniform particle size distribution, and to
conjugate their surfaces with different biocompatible organic coatings.
2. To load crocin efficiently onto the functionalized MNPs.
3. To assess anti-cancer effects of crocin-loaded NPs in vitro utilizing HepG2 cells.
4. To develop HCC animal model utilizing Balb/c mice and then assess the anticancer effect of crocin-loaded NPs.
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Chapter 2: Materials and Methods

2.1. Pure MNPs
Chemicals used to prepare pure MNPs included iron (II) chloride tetrahydrate
(FeCl2-4H2O), iron (III) chloride (FeCl3), sodium hydroxide (NaOH) and ammonia
solution. All reagents were analytical-grade and were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Aqueous solutions of Fe2+ and Fe3+ were separately prepared by
dissolving the respective amounts of FeCl2-4H2O and FeCl3 in de-ionized water. An
aqueous solution of NaOH of pH 13 was also prepared by dissolving the corresponding
amount of NaOH in de-ionized water. A 50 ml aqueous NaOH solution was heated at
60-90oC in an open round flask. A mixture containing equal volumes of Fe2+ and Fe3+
was injected into the NaOH solution at feeding rates of 20, 40 or 60 ml/hr using syringe
pump with vigorous stirring. At the end of addition, a brownish-black precipitate was
formed. The whole solution was vigorously stirred for 60 minutes at a constant
temperature, which is the same as the stirring temperature; 60-90oC. MN suspensions
were then soaked at 60, 75 or 90 ºC for 24 hrs in the incubator. To study the effect of
varying the ionic strengths of the starting solutions on the characteristics of the formed
NPs, Fe2+/Fe3+ solutions containing 0.075/0.15, 0.15/0.3, 0.3/0.6 or 0.6/1.2 were
prepared and initially injected in the NaOH aqueous solution at the optimized feeding
rate, stirring and soaking temperatures.
The MN suspensions were then centrifuged at 3000 rpm for 15 minutes followed
by a successive decantation/washing with 12% ammonia solution for 3 times to maintain
high basic conditions. After final decantation, MN deposits were collected and dried at
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60 ºC for 24 hrs. Dried powders were finely ground to be characterized for its
composition, morphology, surface area, magnetic susceptibility, and magnetization.
Based on the experiments carried out in the previous section, lists of optimized
conditions were obtained. A mixture containing equal volumes of ferrous and ferric salts
was injected into the 5M NaOH solution at feeding rates of 40 ml/hr using a syringe
pump with vigorous stirring. At the end of the addition, a brownish-black precipitate was
formed. The whole solution was vigorously stirred at the same constant temperature
60°C for 60 minutes. MNPs suspensions were then soaked at 60ºC for 24 hrs without
stirring. The MNPs suspensions were then centrifuged at 3000 rpm for 15 minutes
followed by successive decantation/washing with 25% ammonia solution three times.
After the final decantation, the MNPs deposits were collected and dried at 60°C in the
incubator for 24 hrs. The dried powders were finely ground to be characterized in
respect of their composition, morphology, surface area, and magnetic properties.
2.2. Functionalization of MNPs
MNPs were chemically functionalized by applying organic coatings onto its
surfaces. Three types of biocompatible organic compounds were considered; SDS,
chitosan and dextran. The chemical structures of these compounds are shown in Figure
5. In the following sections, the method of applying each of the coatings will be
explained:
2.2.1. SDS-coating onto MNPs
To prepare SDS-coating MNPs, similar process as described above was repeated
with the SDS being initially dissolved in 50 ml water at concentrations of 0.2, 0.5, 1.0
and 2.0% by weight. Each of these solutions was added to 50 ml of 5M NaOH solution
prior to injection of the Fe2+/Fe3+ solution. SDS dissolved gradually when the
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temperature increase to 60°C. The injection of 0.3 M of Fe2+ and 0.6 M of Fe3+ iron ions
into 5 M NaOH solution was at a feeding rate of 40 ml/hr at 60°C in a normal
atmosphere. At the end of addition, a brownish precipitate was formed. The whole
solution was vigorously stirred at 60oC for 1hr. SDS-coated MNPs (called S-MNPs
hereafter) suspensions were then soaked at 60ºC for 24 hrs without stirring. The S-MNPs
suspensions were then centrifuged at 3000 rpm for 15 minutes followed by successive
decantation/washing with 25% ammonia solution three times. Then S-MNPs deposits
were collected and dried at 60°C in the incubator for 24 hrs. The dried powders were
finely ground to be characterized for their composition, morphology, surface area, and
magnetic properties.
2.2.2. Chitosan coating onto MNPs
To prepare chitosan-coating MNPs, chitosan solutions containing 0.2, 0.5, 1.0
and 2.0 % by weight were prepared by dissolving the corresponding weight of chitosan
in a 0.2 % acetic acid solution. An equal volume of each of the chitosan solutions
(around 50 ml) was vigorously blended with 0.3 M of Fe2+ and 0.6 M of Fe3+ solutions
(25ml Fe2+ + 25 ml Fe3+), and then injected into 5M NaOH solution at a feeding rate of
40 ml/hr at 60°C in a normal atmosphere. At the end of addition, a brownish precipitate
was formed. The whole solution was vigorously stirred at a constant temperature of
60oC for 1hr. Suspensions of chitosan-coated MNPs (called C-MNPs hereafter) were
then left to cool to room temperature. The suspension was then decanted and centrifuged
at 3000 rpm for 15 minutes followed by a successive decantation/washing with 25%
ammonia solution for 3 times. After washing out the un-attached chitosan, a Benedict’s
test was used to confirm the complete removal of unattached chitosan. C-MNPs were
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finally dried in air at 60oC for 24 hrs. Completely dried powders were finely ground and
characterized for their composition, morphology, thermal and magnetic properties.
2.2.3. Dextran-coating onto MNPs
To prepare dextran-coating MNPs, dextran solutions containing 0.2, 0.5, 1.0 and
2.0 % by weight were prepared by dissolving the corresponding weight of dextran in a
5M NaOH solution (dissolved completely at room temperature). MN precursors (0.3 M
of Fe2+ and 0.6 M of Fe3+ iron salt solutions) were separately prepared, then injected into
the NaOH solution at a feeding rate of 40 ml/hr at 60°C in air. At the end a brownish
precipitate was formed. The whole solution was vigorously stirred at 60oC for 1hr.
Suspensions of the dextran-coated MNPs (called D-MNPs hereafter) were then left to
cool to room temperature. This was followed by decantation, washing the completely
dried. Dry powders were finely ground and characterized for their composition,
morphology, thermal and magnetic properties.
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Figure 5: Schematic representation of chemical structures of organic coatings. a) SDS,
b) chitosan and c) dextran.

56

2.3. Benedict’s test
A Benedict’s test was used to detect the un-attached chitosan and dextran in the
coated MNPs solutions. A Benedict reagent was prepared by dissolving 173 g sodium
citrate and 100 g sodium carbonate in about 500 ml de-ionized water. Separately, 17.3 g
copper sulfate was dissolved in about 100 ml de-ionized water. After that both solutions
were mixed together with stirring and the volume was completed to 1000 ml with deionized water. To test for unattached chitosan or dextran, few drops of the test solution
were added to 2ml of Benedict reagent, and then boiled for five minutes in a water bath.
Formation of coloured precipitate qualitatively indicates presence of chitosan or dextran
in the solution.
2.4. Addition of cross linker and crocin to D-MNPs
Based on the characterization results of the organic-coated MNPs, 1.0 weight %
of dextran coating MNPs were chosen for further functionalization with crocin.
However, it was found that a linker molecule was required to be immobilized onto the
D-MNPs prior to be functionalized with crocin. To do that, pre-calculated amounts of
1.0% D-MNPs were suspended in autoclaved de-ionize water and under sterilized
conditions until completely dried. The dry powders were divided into two groups: one
group D-MNPs with a linker but without crocin (negative control), and another D-MNPs
group with linker and crocin. The preparations of the D-MNPs groups were performed
simultaneously.
Synthesis of the D-MNPs derivatives were carried out in a dry fresh
dimethylacetamide (DMAC), as a solvent in the absence of moisture.

Succinic

anhydride was added to the groups in a large excess (D-MNPs: succinic anhydride,
1:20). The succinic anhydride-D-MNPs mixture in DMAC was stirred at 90°C for 8 hrs
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in oil bath in a closed environment. At this point, the two groups were treated
differently. D-MNPs with linker but without crocin: unreacted succinic anhydride, from
the above mixture, was removed by repeated washing of the D-MNPs with sterile deionized and stored in fresh sterile de-ionized water. D-MNPs with linker but with crocin:
the second group of D-MNPs was washed three times with DMAC to remove un-bound
succinic anhydride. Each step was followed by centrifugation at 3000 rpm for 15
minutes at room temperature and decantation for 3 times. After that, fresh DMAC and 2
mmol of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI.HCl)
were added to D-MNPs with stirring at room temperature for 12 hrs under moisture-free
conditions.
Following that, 50 or 100 mg/ml Crocin (Sigma-Aldrich, St. Louis, MO, USA)
was added to the DMAC mixture and stirred for 24 hrs at room temperature. Coated NPs
centrifugation and washing with sterile de-ionized water were thoroughly carried out 6
times at 4000 rpm, 15°C for 15 minutes. The resultant crocin-loaded D-MNPs were
precipitated and re-suspended in de-ionized water. UV-Visible spectroscopy and Fourier
transform infrared (FTIR) spectroscopy were performed to confirm the presence of
crocin onto the surfaces of D-MNPs. It should be mentioned that D-MNPs with crocin
samples were named according the concentration tested in vitro or in vivo, 2 mg/ml, 3
mg/ml or 4 mg/ml crocin-loaded D-MNPs formulations.
2.5. Calculation of the crocin loading
Crocin conjugation efficiency was determined by an indirect method. Indirect
method involved detection of total free crocin concentration in the decanted solutions,
after reaction, by measuring the absorbance at 440 nm (visible range) using a UV–
Visible spectrophotometer. The amount of crocin loaded in (or entrapped within) the D-
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MNPs was calculated by the difference between the total amount of crocin initially used
to prepare the NPs and the amount of free crocin present in the decanted solutions [168,
169]. Then the loading efficiency was calculated as the following equation:
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =

(𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑙𝑜𝑎𝑑𝑒𝑑 𝑐𝑟𝑜𝑐𝑖𝑛)
(𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦 𝑎𝑑𝑑𝑒𝑑 𝑐𝑟𝑜𝑐𝑖𝑛)

𝑥 100 Equation 3

2.6. Characterization techniques
All neat and coated MNPs were characterized for their composition, morphology
and properties using various characterization techniques:
The composition was studied by X-ray diffraction (XRD), FTIR spectroscopy,
and thermogravimetric analysis (TGA). An automated Phillips X-ray diffractometer
(Phillips, Amsterdam, Netherland), with a step size of 0.02o, scan rate of 2o per min, and
a scan range from 2 = 10o to 70o was used on dry sample. FTIR analysis was conducted
using a Nicolet Nexus 470 infrared spectrophotometer (Massachusetts, USA), where
samples were pre-pressed with KBr, then scanned over the normal range of 4000–400
cm-1. Thermogravimetric analysis (TGA) was carried out using a TGA-50 Shimadzu
thermogravimetric analyser (Kyoto, Japan), where pre-weighed powder samples were
heated to 600°C at a heating rate of 20°C/min using aluminium pan in air, and the
percent weight loss was followed and correlated with the original composition of the
NPs.
Solid NPs samples were evaluated for their microstructures using a JEOL
Scanning electron microscopy (SEM; XL-30 Phillips, Amsterdam, Netherland) at an
accelerating voltage of 15 kV. Detailed description of the morphology of the NPs was
examined by Transmission electron microscopy (TEM; CM10-Phillips Amsterdam,
Netherland). Samples were prepared for imaging by spreading drops of NPs diluted
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dispersion on a copper grid that was coated with a thin layer of carbon and then air
dried.
Porosity, pore size distribution and pore volume of the dried solid samples were
measured using liquid nitrogen adsorption at 77 K employing a Quantochrome NOVA
1000 volumetric gas sorption instrument; Autosorb (Boynton Beach, FL,USA).
Magnetic properties of the NPs were studied by measuring the magnetic
susceptibility of the neat and coated NPs as a function of coating concentration.
Moreover, the magnetization of these NPs as a function of applied magnetic field at
room temperature and was measured using a vibrating sample magnetometer (VSM,
Quantum design Inc, San Diego, CA, USA) instrument.
2.7. In vitro release study of crocin
Crocin release behaviour of the prepared crocin conjugated D-MNPs was studied
in physiological pH (7.4) as well as in acidic media at pH 5.5. Two samples of 2 and 4
mg/ml crocin loaded D-MNPs with 3 mg Fe/ml were prepared in 1.5 ml of 1x phosphate
buffered saline (PBS) at pH values 5.5 and 7.4. The samples were kept in the incubator
at 37ºC under constant mixing. In order to determine crocin concentration, and thereby
follow up the time dependent crocin release profile, clear 1.5 ml of supernatant samples
were taken out after precipitating the NPs at pre-determined time intervals. Each
removed volume was replaced by 1.5 ml of fresh buffer solution of the same pH value.
Then the NPs were maintained back at 37 ºC after mixed and re-suspended properly.
The concentration of drug released was determined by UV–Visible spectrophotometry at
440 nm and using calibration curve of free crocin. The percentage of crocin released was
calculated as in the following equation:
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𝑅𝑒𝑙𝑒𝑎𝑠𝑒 (%) =

(𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓𝑓𝑟𝑒𝑒 𝑐𝑟𝑜𝑐𝑖𝑛 in supernatant after release test)
(𝑎𝑚𝑜𝑢𝑛𝑡 of crocin initially in D−MNPs before release test)

𝑥 100

Equation 4

To calculate the percentage of cumulative release of crocin, individual percentage
release values were added to each other.
2.8. In vitro cytotoxicity
HepG2, a human hepatocellular carcinoma cell line, was purchased from
American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were
maintained in 75 cm2 culture flasks using Dulbecco´s Modified Eagle´s Medium
(DMEM) (Life Technologies, Grand Island, NY, USA), supplemented with 10% heatinactivated fetal bovine serum (Life Technologies, Grand Island, NY, USA) and 1%
penicillin/streptomycin. Cells were grown in 5% CO2 at 37 °C and 100% humidity.
Media were changed every 48 hrs, and the cells were sub-cultured after 5 - 6 days using
1x trypsin- Ethylenediaminetetraacetic acid (EDTA), (Life Technologies, Grand Island,
NY, USA).
2.8.1. MTT Assay
The viability of HepG2 cells was determined by measuring the reduction of 3[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) to insoluble purple
formazan (Sigma-Aldrich, St. Louis, MO, USA). The yellow tetrazolium salt MTT is
reduced by metabolically active cells, in part by the action of dehydrogenase enzymes
(reductase) in mitochondria, to generate reducing equivalents such as NADH and
NADPH. The resulting intracellular purple formazan can be solubilized and quantified
by spectrophotometry. So the living cells were purple, while dead cells were colourless.
HepG2 cells were seeded at density of 8000 cells/well in a 96-well plate for 24
hrs for the cells to attach to the plate. Then, the medium was changed into fresh medium
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with following treatments. Various concentrations of crocin including 0.025, 0.05, 0.5,
3, 5, 8, 10, 15 or 20 mg/ml were tested. Different iron concentrations including 0.05,
0.07, 0.09 or 0.1 mg Fe/ml in D-MNPs were tested. Cells were incubated with 3 mg/ml
crocin, D-MNPs and 3 mg/ml crocin-loaded D-MNPs. D-MNPs that have been tested
contained 0.09 mg/ml (9 µg/100 µl) iron content in D-MNPs [3]. After 72 hrs incubation
period, cells were washed with 1x PBS and then 100 µl new medium was added to each
well in addition to 20 µl of MTT (5 mg/ml). Cells were then incubated at 37°C for 1 hr.
After that the formazan solubilized using 100 µl isopropanol for 30 minutes at room
temperature and the absorbance was measured at 560 nm.
All the tested groups were well dissolved/suspended in DMEM prior incubating
them with the cells. The relative cell viability (%) related to control wells containing
cells culture medium without any treatment was calculated as the following equation:
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =

(Absorbance of tested compound)
(Absorbance of control)

𝑥 100

Equation 5

2.9. In vivo study
2.9.1. Animals
Balb/c mice were obtained from the animal facility of the College of Medicine
and Health Sciences, UAE University. Animals were housed under a 12 hrs light/dark
cycle each at 24–26°C. They were maintained on standard laboratory animal diet with
food and water ad libitum. All animal studies were carried out in accordance with, and
after approval of, the Animal Research Ethics Committee of the College of Medicine
and Health Sciences, UAE University.
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2.9.2. Experimental design
In the present study, 3-weeks old male Balb/c mice were used. These mice were
randomly divided into 2 groups; Normal group (n=3) which did not receive any
treatment and experimental group (n=9). The experimental group was treated with 50
mg/kg body weight of DEN (Sigma-Aldrich, St. Louis, MO, USA) dissolved in saline
(0.9% NaCl) and given i.p. injections twice a weeks for 8 weeks, total of 16 injections.
Then, the mice of experimental group were randomly divided into four sub-groups
(n=3) and injected intravenously (i.v.) in the tail as the following: Sub-group 1 (DENinduced) received 100 µl of saline twice a week for two weeks, total of 4 injections.
Sub-group 2 (Crocin) received 100 µl of crocin dissolved in saline twice a week for
two weeks, total of 4 injections. The injected concentrations were 11 mg/kg or 22 mg/kg
in two different experiments. Sub-group 3 (Crocin-loaded D-MNPs) received 100 µl
of 11 mg/kg or 22 mg/kg crocin loaded D-MNPs formulations in saline twice a week for
two weeks, total of 4 injections. The injected concentrations were equivalent to 17 mg
Fe/kg (0.3 mg Fe/100 µl) of D-MNPs as iron concentration in the two different
formulation experiments. This dose was chosen 0.3 mg/100µl twice a week for two
weeks was reported non-toxic [170].
At the end of experimental period, that was 24 hrs after the last i.v. injection,
mice were weighed, anesthetized by mild Diethyl ether and dissected (Figure 6). The
whole liver was removed, weighed, and examined for the presence of visible lesions or
tumour. The right lobe was cut into small parts and fixed in 10% buffered formalin for
24 hrs. Fixed tissues were then processed for dehydration in ascending grades of ethanol
(70% and 90% each for 1 hr, after that 100% twice and each was for 2 hrs). Tissues were
then cleared in xylene and finally impregnated and embedded in paraffin.
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A total of 4 different livers (representative of each normal and experimental
groups) were embedded in the same block. Paraffin tissue blocks were cut at 5 microns
thickness, mounted on gelatine-coated slides and then used for histopathological and
immunohistochemical (IHC) studies (Figure 7). For histopathological examination the
slides were stained with hematoxylin and eosin (H&E).
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Figure 6: A diagram representing the treatment regime of the DEN-induced animal
model and groups assignment.
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Figure 7: Diagrammatic representations of liver sections that were processed to
perform several studies.
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2.9.3. Prussian blue stain
Prussian blue staining was used to study the presence of iron. Tissue sections
were deparaffinized in xylene, rehydrated in descending grades of ethanol (100%, 95%,
90%, 70% and 50% each for 3 minutes), and washed in distilled water. Equal parts of
ready prepared solutions of 20% hydrochloric acid and 10% potassium ferrocyanide
were mixed immediately before used for slide incubation for 35 minutes. Sections were
washed with distilled water and counterstained with neutral red for 25 minutes or with
H&E stain.
2.9.4. Immunohistochemistry (IHC) studies
Liver tissue sections were deparaffinized in xylene, rehydrated in descending
grades of alcohol (100%, 95%, 90%, 70% and 50% each for 3 minutes), and washed in
1x PBS. Sections were incubated in antigen retrieval solution 10 mM Citrate buffer at
pH 6 and heated at 98°C for 45 minutes. To inhibit endogenous peroxidase activity,
sections were incubated in 3% hydrogen peroxide in methanol for 1 hr at room
temperature. A circle with a thin film using PAP-pen (Dako, Glostrup, Denmark) was
draw around the tissue sections to ensure that all tissue sections were exposed
simultaneously to the same solution/ reagents.
To ensure similar conditions to all tissue sections, all the tested groups were run
at the same time and slide using similar conditions. Tissue sections from all tested
animal groups were included on the same slide (Normal, DEN-induced, Crocin, and
Crocin-loaded D-MNPs). To block non-specific binding, sections were incubated in 1%
bovine serum albumin containing 0.5% Tween-20 in 1x PBS for 45 minutes. Sections
were then incubated 1 hr at room temperature or overnight at 4°C with rabbit polyclonal
primary antibodies as mentioned in Table 4.
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Following a PBS wash, tissue sections were incubated with biotinylated donkey
or sheep anti-rabbit antibodies (Jackson ImmunoResearch, West Grove, PA, USA;
1:500) for 2 hrs at room temperature. To use avidin-biotin-peroxidase complex (ABC)
method, Extravidine peroxidase conjugate (Sigma-Aldrich, St. Louis, MO, USA;
1:1000) was added for 1 hr at room temperature in 1% bovine serum albumin. The
antigen-antibody binding sites were revealed by using 3,3’-diaminobenzidine
tetrahydrochloride (DAB, Sigma-Alrdich, St. Louis, MO, USA). Some of the tissues
were counterstained briefly with the hematoxylin being added for around 1 minute. After
that sections were dehydrated through graded ethanol, cleared in xylene and mounted
using DPX. Negative control slides were prepared by replacing the primary antibody
with PBS.
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Table 4: Primary antibodies used for IHC studies.

Antibody
Glutathione S-transferase
placental form (GST-P)

Dilution
factor

Incubation
Time

Manufacture

1:1500

1hr

MBL Co.,Ltd.,
Nagoya, Japan

Ki-67

1:1000

1hr

Abcam,
Cambridge, MA,
USA

M30-Cytodeath

1:100

Overnight

Roche, Penzberg,
Germany

Overnight

Abcam,
Cambridge, MA,
USA

Overnight

Abcam,
Cambridge, MA,
USA

Overnight

Abcam,
Cambridge, MA,
USA

Bcl-2

COX-2

VEGF

1:200

1:200

1:100
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2.9.5. Quantification analysis of primary antibodies expression
To provide a quantification evaluation of the primary antibodies expression in the
stained tissue, DAB labeled tissue sections were calculated using a computerized
method. This method depended on automated process of quantification of DAB stained
cells in different tissue samples, by using digital image processing via Image Pro 6
software. The method was estimating the percentage (%) area of expression per image or
field at 400 magnifications. A total of 20 fields per antibody labeled tissue sections were
quantified. The automated quantification was followed, because it minimized the human
error and gave more accurate data.
2.10.

Statistics
The resulted data were represented as mean ± the standard error of the means.

The mean of the groups were compared using GraphPad Prism 5 software and one-way
analysis of variance (ANOVA) with Tuckey post-hoc procedure. Data were considered
significantly different at a value of P ≤ 0.05 and highly significant at P ≤ 0.001.
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Chapter 3: Results and Discussion

3.1. Characterization of pure MNPs
MNPs were prepared in the current study using a modified wet method in air.
Formation of different types of iron oxides in aqueous media has been studied from
the electrochemical point of view using Pourbaix diagrams [171]; Figure 8. In highly
basic aqueous media, Pourbaix diagrams indicated that other phases such as FeO42-,
Fe2O3, Fe(OH)2 and HFeO2- may also exist under these conditions. These phases
could be distinguished from each other using various characterization techniques
such as XRD and FTIR. In addition, MN, Fe3O4, has been viewed as an assembly of
FeO and Fe2O3 within a unified crystal lattice of MN [172].
When synthesized in air, FeO gets oxidized to Fe2O3, leaving a phase-pure
Fe2O3, according to Equation 6:
2(FeO.Fe2O3) + ½ O2 → 3 Fe2O3

Equation 6

Fe3O4 + ¼ O2 + 4½ H2O → 3Fe (OH)3

Equation 7

Oxidation reactions shown in Equations 6 and 7 explain why synthesis of
MNPs in alkaline media in air has been always abandoned to avoid the formation of
phase-impure Fe3O4. However, if solutions were pre-adjusted to be highly alkaline
prior the addition of Fe2+ and Fe3+ ions then MN would be spontaneously
precipitated as the highest thermodynamically stable phase despite the fact that all
preparations were carried out in air. In the current study, aqueous media used for the
preparation of MNPs were pre-adjusted at a pH 13 using NaOH to avoid the
formation of non-MN phases.
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Figure 8: Pourbaix diagram for the iron-water system showing the
thermodynamically stable phases in aqueous solutions with various pH values.
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Various parameters were investigated for their effect on the purity of the
deposited MNPs. Figure 9 shows XRD patterns of the phases evolved during the
formation of MN as a function of the feeding rate, while keeping the stirring and
soaking temperatures as well as the starting concentrations of Fe2+ and Fe3+ constant.
The XRD patterns in Figure 9 compare the phase purity and crystallinity of
MNPs formed at feeding rates 20, 40 or 60 ml/hr. A standard JCPDS pattern of pure
MN is also shown for comparison. At a fast feeding rate of 60 ml/hr, the deposited
MN nuclei rapidly formed and accumulated without further crystallization leading to
an amorphous phase, which also shows a relatively weak intensity peak at 2θ value
of 35.2º for the 311 plane. These results indicated the need for a slower rate of
addition of the iron reactants. At a slower feeding rate of 40 ml/hr, relatively more
time was given for the deposited nuclei to crystallize. This was even increased by
decreasing the feeding rate to 20 ml/hr, as indicated by the presence of the MNPs
characteristic peaks at 2θ values of 29.9º (220), 35.2º (311), and 43.1º (400). In
addition to these findings, no indication for the presence of non-MN phases was
observed despite the fact that the entire preparation process took place in air.
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Figure 9: XRD patterns of solid MNPs prepared at different feeding rates of Fe2+
and Fe3+ aqueous solutions. JCPDS: Joint Committee on Powder Diffraction
Standards.
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Figure 10 shows SEM micrographs of agglomerates of MNPs prepared at
different feeding rates. These micrographs indicate the formation of rounded NPs
with homogeneous size distribution at all feeding rates. The average agglomerate
size and surface area of the deposited MNPs is shown in Table 5-black colour.
Despite the difference in crystallinity of the formed NPs at different feeding rates, a
less pronounced variation in the average particle size was detected.
Given the phase purity of MNPs formed at these conditions, a feeding rate of
40 ml/hr was chosen for the optimization of the following preparation parameters.
Stirring temperature during and after the addition of the Fe2+ and Fe3+ ions to the preadjusted alkaline solution was varied at 60, 70, 80 or 90 ºC. This is shown in Table
5-blue colour to have a pronounced effect on the average particle size and surface
area of the formed NPs without affecting the overall crystallinity or purity of the
MNPs. The least agglomerate average particle size of 55 nm was achieved at a
stirring temperature of 60ºC. Size increased by raising the stirring temperature up to
90ºC.
Figure 11 shows SEM micrographs of agglomerates of MNPs prepared under
different stirring temperatures. An overall homogeneous size distribution of the NPs
forming these agglomerates is evident. Moreover, increasing the size of the NPs with
increasing the stirring temperature was also reflected in an increase in the size of the
agglomerates.
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Figure 10: SEM micrographs of agglomerates of MNPs prepared at different
feeding rates. a) 20ml/hr, b) 40ml/hr and c) 60ml/hr.
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Figure 11: SEM micrographs of agglomerates of MNPs prepared under different
stirring temperatures. a) 60°C, b) 70°C, c) 80°C and d) 90°C.
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Previous researchers showed that only kinetic factors control the growth of
the crystal. In a coprecipitation process where Fe2+ and Fe3+ ions are added at the
same time, the mechanism of precipitation of MNPs takes place over two stages
[102]. The first stage involves a short burst of nucleation as the concentration of the
species reached critical super-saturation. This step is followed by a slow growth of
the nuclei by diffusion of the ionic species in solution to the surface of the formed
MN crystallites as in Figure 12. This step is believed to be enhanced by increasing
the stirring temperature during the addition of the iron species.
Moreover, and in contrast to an average size of 15 and 26.5 nm of the MNPs
obtained at a stirring temperature of 80 ºC under N2 gas in the work of Zhang et al.
[173] and Lee et al.[174], the relatively higher size obtained in the current study; at
60 ºC, could be attributed to the fact that all preparations were carried out in air. At a
lower temperature range (4–37 ºC), and using NaNO2 as an oxidant, a controlled
oxidation of Fe2+ in an alkaline media under N2 gas took place forming MNPs with a
size range of 30–100 nm [175]. Although reactants used in this system were different
from the currently studied one, its findings indicate that despite the presence of N2
atmosphere, NPs with a relatively large size could be obtained at temperatures below
60 ºC.
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Figure 12: Diagrammatic representation of the nucleation and growing process of
MNPs, modified from [176].
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After complete addition of reactants, precipitated MNPs were maintained in
contact with their alkaline solutions for 24hr at soaking temperatures of 60, 75 or 90
ºC (Table 5-red colour). Soaking of the MNPs at relatively high temperatures
following their co-precipitation was previously shown to enhance crystallinity, which
was also shown to be a function of the soaking temperature [177].
The effect of varying the soaking temperature on the average particle size and
surface area of the NPs is given in Table 5-red colour. No change was observed in
the size and surface area of the NPs when the suspensions were soaked at the same
temperature as that maintained during the addition and stirring of reactants.
Increasing the soaking temperature up to 90ºC led to an increase in the particle size
accompanied by a consequent decrease in the surface area of the formed NPs. This
indicates that the observed growth of the formed NPs is temperature-dependent. It
should be mentioned that varying the soaking temperature did not affect the
crystallinity of the formed NPs. It was, therefore, recommended to maintain the
stirring and soaking temperatures at the same value whereas the optimized
temperature was at 60ºC at a 40 ml/hr feeding rate.
Based on these findings, MNPs prepared in solutions containing different
concentrations of Fe2+ and Fe3+ were further characterized in more details. These
concentrations included: 0.075/0.15, 0.15/0.3, 0.3/0.6 and 0.6/1.2 of Fe2+ and Fe3+,
respectively. The data shown in Table 5-green colour indicate that doubling the
initial concentrations, while maintaining a fixed solution volume, resulted in a
pronounced increase in the agglomerate average size of the precipitated NPs, with a
consequent decrease in the surface area of the NPs. This was also shown in the SEM
micrographs of these samples; as shown in Figure 13. This was also reflected in an
increase in the crystallinity of the formed MNPs.
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Figure 13: SEM micrographs of different concentrations of Fe2+ and Fe3+. a)
0.075/0.15, b) 0.15/0.3, c) 0.3/0.6 and d) 0.6/1.2 of Fe2+ and Fe3+, respectively.
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Table 5: Effect of different conditions on the agglomerate average particle size and
surface area of MNPs prepared by a co-precipitation in an aqueous solution.
[Fe2+]/Fe3+]

Feeding
Rate
(ml/hr)

Stirring
Temperature
(oC)

Soaking
Temperature
(oC)

Average
Particle
Size (nm)

Surface
Area
(m2/g)

0.30/0.60
0.30/0.60
0.30/0.60
0.30/0.60
0.30/0.60
0.30/0.60
0.30/0.60
0.30/0.60
0.30/0.60
0.30/0.60
0.075/0.15
0.15/0.30
0.30/0.60
0.60/1.20

20
40
60
40
40
40
40
40
40
40
40
40
40
40

60
60
60
60
70
80
90
60
60
60
60
60
60
60

60
60
60
60
60
60
60
60
75
90
60
60
60
60

76
55
85
55
165
290
350
55
165
189
25
40
55
175

197
215
167
215
140
81
72
215
140
122
460
230
215
162
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Figure 14 shows XRD patterns of MNPs prepared using different initial
concentrations of the starting iron ions. Peaks appeared at 2θ values of 29.9º (220),
35.2º (311), 43.1º (400), 53.4º (422), 57.1º (511), and 62.8º (440) were observed in
all samples, and were consistent with the standard data of phase-pure MNPs shown
in Figure 9 [102, 174]. Despite the fact that the current experiments were carried out
in air, no sign of oxidation of the formed MN was found, reflecting its chemical
stability. The relative broadening of the peaks at 29.9º, 35.3º and 62.8º in samples
made of solutions containing Fe2+/Fe3+ 0.075/0.15 ratio is attributed to relatively
small particle size, which is known to be as a result from dilute solutions [174], and
is shown in Figure 13a. The absence of maghemite in the XRD patterns of the
MNPs prepared in the current study confirms the phase purity of the prepared MNPs.
Figure 15 shows a FTIR spectrum of a selected MNPs sample prepared in
solutions containing initial concentrations of 0.3 and 0.6 M of Fe2+ and Fe3+ ions,
respectively. Bands at wavenumbers of 430, 584and 622 cm-1 are characteristic to the
Fe-O stretching absorption in MN phase, while the broad band around 3400 cm-1 is
characteristic to the stretching mode of absorption of the O-H bond in the physically
adsorbed water molecules [178]. Being prepared in aqueous media, MNPs show the
presence of physically adsorbed water molecules even after drying in air, since there
is no possibility for water molecules to be included within the crystalline structure of
MN.
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Figure 14: XRD patterns of MNPs prepared using different initial concentrations of
the starting iron ions Fe2+/Fe3+.
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Figure 15: FTIR spectrum of MNPs sample containing initial concentrations of 0.3
and 0.6 M of Fe2+ and Fe3+ ions, respectively.
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The presence of physically adsorbed water was also confirmed by TGA
analysis; Figure16, which shows the percent weight loss of solid MNPs when heated
up to 600oC in air. These TGA curves were collected for MNPs samples that were
prepared from solutions containing various concentrations of the initial Fe2+ and Fe3+
solutions. All samples showed weight loss values in the range of 14–17% taking
place at a mid-temperature of 100 ºC. This is attributed to the evaporation of the
physically adsorbed water. This loss continued to take place with a slower rate as
temperature increased. This could be attributed to the presence of multi layers of
water of hydration onto the surfaces of the NPs. It should be mentioned that after
complete dryness of all powders, NPs were highly agglomerated, which a common
characteristic of small NPs is prepared in aqueous media [101, 111].
The MNPs prepared in the current study are intended to be used as drug
delivery vehicles to treat hepatic cancer. Therefore, in addition to biocompatibility of
the NPs, size and surface area of the NPs are considered important parameters that
will determine the affinity towards the immobilization of drugs onto their surfaces as
well as the efficiency of drug delivery. MNPs prepared from solutions containing
various initial concentrations of the Fe2+ and Fe3+ ions were subjected to surface area,
porosity and pore size distribution measurements using liquid Nitrogen adsorption
technique. Figure 17 shows the adsorption isotherms of N2 on agglomerated
powders prepared under these conditions. All samples showed hysteresis loops of
type IV where the lower curve represents the adsorption of N2 gas on the surfaces of
the NPs, while the upper curve represents the progressive withdrawal; desorption, of
the adsorbed N2 gas [179].
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Figure 16: TGA analysis of solid MNPs samples prepared in solutions containing
different initial concentrations of Fe2+ /Fe3+ ions.
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Figure 17: Adsorption isotherms of MNPs samples prepared in solutions containing
different initial concentrations of Fe2+ /Fe3+ ions. a) 0.075/0.15, b) 0.15/0.3, c) 0.3/0.6
and d) 0.6/1.2 of Fe2+ and Fe3+, respectively.
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As a result of the isotherms in Figure 17, pore size distributions were
calculated using the BJH method for the desorption segment of the hysteresis curves.
Results are plotted in Figure 18. All samples showed homogeneous pore size
distributions with maxima in the range of 30–40 nm. This range denotes the presence
of mesoporosity in the agglomerates of the prepared NPs [179]. A mesoporous
material is a material containing pores with diameters between 2 and 50 nm. The
monodispersity in the pore size distribution within the agglomerates relatively
reflects the homogeneity of the particle size distribution in these samples. No
pronounced difference in the pore size or its distribution was observed among
samples prepared from solutions containing various concentrations. The homogenous
distribution of mesopores in the aggregates of the prepared NPs offers an advantage
for these NPs if they are used for environmental applications.
Detailed morphology of the MNPs prepared in solutions containing
0.075/0.15 and 0.3/0.6 M concentrations of Fe2+ and Fe3+ ions, respectively is shown
in the TEM micrographs in Figure 19. MNPs shown in the TEM micrographs are
spherical in shape with a homogeneous size distribution. The average sizes of these
individual NPs were 12 ±5 and 25 ±5 nm, for samples prepared from relatively dilute
solutions (Fe2+/Fe3+ = 0.075/0.15) and relatively more concentrated solutions
(Fe2+/Fe3+ = 0.3/0.6), respectively. The relatively smaller particle size shown in
Figure19a explains the relatively small crystallite size of this sample that was
previously shown in Figure 14.
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Figure 18: Pore size distribution in MNPs samples prepared in solutions containing
different initial concentrations of Fe2+/Fe3+ ions. a) 0.075/0.15, b) 0.15/0.3, c) 0.3/0.6
and d) 0.6/1.2 of Fe2+ and Fe3+, respectively.
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Figure 19: TEM micrographs of MNPs prepared in solutions containing different
initial concentrations of Fe2+ and Fe3+ ions. a) 0.075/0.15 and b) 0.3/0.6 M of
Fe2+/Fe3+ ions. Insets: individual round shaped MNP.
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The magnetic susceptibility results of MNPs samples prepared at different
starting concentrations of Fe2+ and Fe3+ ions are shown in Figure 20. Magnetic
susceptibility is the degree to which a material can be magnetized in an external
magnetic field, and is directly proportional to its magnetization [180]. Moreover, the
magnetic size is known to be directly proportional to the magnetic susceptibility of
solid NPs [181].
Susceptibility results indicate an opposite behaviour, but are still explained by
their agglomeration and size characteristics. Previous results by Thapa et al. [182]
attributed the increase in the magnetization of MN with the decrease of particle size
to the decrease in the oxygen content in the MN samples and the subsequent increase
of [Fe2+] in the MN lattice, which is the main cause of magnetic character of MNPs.
Moreover, Ma and Liu related the decrease in magnetic properties with increasing
size of MNPs to the agglomeration of the particles, which is caused by the
hydrophobic interaction between them [183].
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Figure 20: Magnetic susceptibility of MNPs prepared in solutions containing
different initial concentrations of Fe2+ and Fe3+ ions.
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Based on the previous results, MNPs prepared using the following optimum
conditions were used for the next stage of experimentation where organic coating
materials were developed onto their surfaces:
a) Fe2+/Fe3+ = 0.3/0.6 M
b) Feeding rate of 40 ml/hr
c) Stirring temperature of 60oC
d) Soaking temperature of 60oC
Under these conditions, monolithic MNPs with a spherical shape that exhibited
superparamagnetic behavior at room temperature [184]. The average particle size of
these MNPs were in the size of 25 nm with the high surface area; around 215 m2/g as
seen in Table 5. However, and due to small size of MNPs that form high surface-tovolume ratio and magnetic properties of the NPs, agglomeration took place giving
rise to mesoporous agglomerates with an average size of 55 nm. MNPs prepared
under these optimum conditions were further subjected to magnetization
measurements as a function of applied field at a room temperature. Results are
shown in Figure 21. A maximum magnetization of 25 emu/g was obtained, which is
lower than that mentioned in the literature for NPs prepared under similar conditions.
This could be attributed to agglomeration of the NPs.
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Figure 21: Magnetization of MNPs prepared under optimum conditions as a
function of applied magnetic field at room temperature.
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3.2. Characterization of different surface coating materials
MNPs have been widely explored for their applications as MRI contrast
agents, in immunoassays, in the detoxification of biological fluids, in hyperthermia,
drug delivery, cell separation, in addition to their environmental applications in the
removal of inorganic contaminants from the aqueous media [102, 185]. However,
MNPs tend to agglomerate in solution, which may limit their applications. For
example, neat MNPs undergo non-specific interactions with the serum proteins in
vivo leading to their rapid elimination from the body. Therefore, it has been
recognized by researchers that the surfaces of the MNPs need to be hydrophilic in
nature for in vitro and in vivo applications, so that it will be stable for prolonged
circulation inside the body [95].
In order to widen the scope of these applications, researchers have explored
the functionalization of the surfaces of these NPs using various organic and inorganic
coatings [87, 92, 178, 186-189]. The choice of coating is application driven. In
biomedical applications, a pre-requisite is to have a biocompatible coating. In
addition, if these coated NPs are to be used to deliver certain bioactive drugs into
infection or tumor sites, the chemical characteristics of the coating should match
those of the bioactive drugs to ensure bonding between them until delivery takes
place [186, 190, 191].
Applying an organic coating onto the surfaces of MNPs takes place by
synthesizing the NPs in the presence of these organic molecules or by chemically
treating the fresh MNPs in solutions of these organic compounds by direct
immersion. The first route provides two advantages over the second one. First, when
organic molecules are initially added to the preparation solution, they tend to act as
capping agents. They adsorb onto the surfaces of the freshly formed MN nuclei,
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hence limiting their size and size distribution. Second, the presence of organic
functionalities onto the surfaces of all formed MNPs helps separating the NPs,
consequently minimize their aggregation. To summarize, the presence of organic
functionalities onto the surfaces of MNPs provides the following advantages:
1) Reduces the aggregation between the MNPs, therefore increases the stability
of the MNPs in various solvents.
2) Controls the size of the MNPs and might help in determine their shape.
3) Improves the biocompatibility of coated MNPs.
4) Limits non-specific cell binding in biomedical application.
5) Provides functional groups for further modification, such as attachment of
optical dyes, therapeutic and targeting molecules.
In the current study, coating of the optimally prepared MNPs was
investigated in details in order to choose the type of functionality that will be further
modified for targeted drug delivery application. Three organic compounds were
studied; SDS, chitosan and dextran. Chemical structure of these organic compounds
is shown in Figure 5. SDS is a known ionic organic compound that has been
previously shown to stabilize NPs in solutions by providing surface charges onto
their surfaces [165, 166]. Chitosan and dextran are natural polymers, and both have
also been shown to stabilize MNPs in solution [114, 117, 118, 144, 147, 148]. The
following sections discuss the characterization of the coated MNPs with each of
these compounds.
S-MNPs and D-MNPs were prepared by addition of Fe2+ and Fe3+ solutions
into an aqueous NaOH solution that was pre-adjusted at pH 13 and containing 0.2,
0.5, 1.0 and 2.0% by weight of SDS or dextran. After precipitation of NPs, they were
centrifuged, washed, dried, and then subjected to characterization. Due to the
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insolubility of chitosan in aqueous and basic media, C-MNPs were prepared by a
different approach. Initially, chitosan solutions containing 0.2, 0.5, 1.0 and 2.0 % by
weight were prepared by dissolving the corresponding weight of chitosan in 0.2 %
acetic acid solution. An equal volume of each of the chitosan solutions was then
added and vigorously mixed with the Fe2+/Fe3+ solutions (pre-coating procedure),
then injected into the NaOH solution at a feeding rate of 40 ml/hr at 60°C in air
(optimal conditions). At the end of addition, extra chitosan was washed out by cycles
of washing and decantation with de-ionized water and confirmed by Benedict’s test,
which is used to detect carbohydrates. The formed C-MNPs were separated by
decantation, centrifuged, washed, and then dried before being characterized for its
composition.
3.2.1. FTIR of coated MNPs
Figures 22-27 show FTIR spectra of S-MNPs, C-MNPs, and D-MNPs,
respectively as a function of the initial concentration of the organic coating; 0.2-2
weight %. A spectrum of pure organic coating; SDS, chitosan and dextran, is also
shown in the respective graph for comparison. In all spectra, MN is represented by
its bands at 430, 584 and 622 cm-1, with band intensities decreasing and shifting to
lower wavenumbers with increasing the concentration of the organic coating. This is
attributed to possible chemical interaction between the functionalities of the organic
coating and the underlying MNPs surfaces. On the other hand, bands of each of the
organic coating compounds were shown to dominate the spectra with increasing the
initial concentration of the organic coating.
The FTIR spectrum of pure SDS in Figure 22 shows the presence of bands at
998.5, 1019.3 and 1082.2 cm-1 for its symmetric absorption, and at 1223.1 and
1248.9 cm-1 for its asymmetric absorption of the -OSO3-- in the -OSO3Na groups in
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SDS [192]. Position, shape, and sharpness of these bands in the FTIR spectra of SMNPs samples in Figure 22 changed as a result of the interaction between the SDS
coating and the underlying MNPs. Details of these changes are given in Table 6.
Shifts in the band position of the corresponding bands in S-MNPs are attributed to
the formation of ionic bonds between the sulfate group and the Fe2+ and Fe3+ ions
along the surfaces of the underlying MNPs (Figure 23), which was previously shown
in comparable oxide systems [192]. This shift was shown to increase with increasing
the concentration of SDS initially added to solution, and was more evident in the
FTIR spectra of S-MNPs samples containing 1.0 and 2.0% of SDS. It should be
mentioned that un-adsorbed SDS was removed from all samples by washing, which
confirms that the observed bands are solely related to SDS coatings.

Table 6: Wavenumber of the absorption bands characteristic to the sulfate group in
SDS as appeared in pure SDS and S-MNPs FTIR spectra.
s (-OSO3-)
as (-OSO3-)
998.5
1019.3
1082.2
1223.1
1248.9
SDS
1010.2
***
***
0.2 %
1005.3
1247.6
***
0.5 %
969.2
1242.1
1062.8
1.0 %
957.8
1229.9
1062.8
2.0 %
*** bands were not observed in the FTIR spectra of these samples
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Figure 22: FTIR spectra of pure SDS and MNPs coated with various concentrations
of SDS.
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Figure 23: Diagrammatic representation of the interaction between SDS functional
groups and iron ions of MNPs to form S-MNPs.
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The characteristic bands of pure chitosan are shown in Figure 24. Those
bands appeared at 1082, 1382 and 1655 cm-1, and are attributed to the absorption of
C-O, C-N, and C=O groups, respectively. In addition, a weak-medium intensity
broad band appears at 3449 cm-1, which is attributed to the absorption of both O-H
and N-H groups, as shown in the chemical structure of chitosan. A summary of these
bands as a function of coating concentrations is shown in Table 7.
A shift towards a shorter wavenumbers was observed in the bands
characteristic to C-O, and O-H/N-H groups, while no pronounced shift was observed
in the bands characteristic to the C-N bond of the amide group. Moreover, another
shift was observed in the absorption band of the amide C=O group. Variation of the
bands of MNPs and those of chitosan in the FTIR spectra of C-MNPs collectively
indicates the formation of bonds between the chitosan coating, as a capping
molecule, and the underlying MNPs surfaces.
These chemical interactions are expected to take place between the MN
surface Fe2+ and Fe3+ ions and the C-O- groups that result from the ionization of the
C-OH groups under the high basic conditions of the experiments (Figure 25). In
addition, coordination bond is expected to form between the C=O group and both
MN Fe2+ and Fe3+ cations, as a result of the extra electronic density on the oxygen
atom of the C=O group. According to the chemical structure of chitosan, it can be
concluded that this interaction takes place at the pending primary alcoholic group
along the chitosan chains as well as the terminal OH groups in every chitosan chain.
Secondary alcoholic groups; directly attached to the hexagonal rings of chitosan, are
sterically hindered and are therefore slightly expected to participate in this interaction
with the MN surfaces. It should be mentioned that un-adsorbed chitosan was
removed by successive centrifuge and washing to eliminate the possibility of un-
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reacted chitosan remain in the powder. Therefore, the relative increase in intensity of
the bands characteristic to chitosan, mentioned in Table 7 with the increase in the
concentration of chitosan indicates the adsorption of more chitosan molecules or the
development of thicker chitosan coatings on the surfaces of the MNPs [173, 193].

Table 7: Wavenumber of the absorption bands characteristic of chitosan, both as
neat and different concentrations coating the surface of MNPs.
[Chitosan]
(Weight %)
100
0.2
0.5
1.0
2.0

υs (C-O)
1082
1076.3
1074.7
1074.7
1069.4

Band location (cm-1)
υs (amide)
υs (C=O)
1382
1655
1384.7
1630.4
1384.7
1628.8
1384.7
1630.4
1384.7
1631.1

υs (O-H & N-H)
3449
3399.8
3399.8
3402.6
3402.6
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Figure 24: FTIR of pure chitosan and MNPs coated with various concentrations of
chitosan.
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Figure 25: Diagrammatic representation of the interaction between chitosan
functional groups and iron ions of MNPs to form C-MNPs.
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Figure 26 compares the FTIR spectra of pure dextran and different
concentrations of dextran coatings onto MNPs. The spectra present vibrational
modes characteristic of the organic structure of dextran, such as the α-glucopyranose
ring of dextran at 907 cm-1. The α-glucopyranose ring in a pure dextran is also
represented by two bands at 759 and 838 cm-1. In addition, bands of pure dextran at
1279 and 1373 cm-1 are due to C-H vibrational modes, while bands at 1019 and 1152
cm-1 are attributed to C-O vibrations (Figure 27). Vibrational bands at 1645 and
3400 cm-1 are representative of O-H group of adsorbed water in the samples. All
dextran bands were shifted and changed their intensities upon the formation of
coatings onto MNPs, as a result of the interaction between dextran and Fe2+ and Fe3+
ions in the MNPs surfaces, as summarized in Table 8 [178, 194, 195].

Table 8: Wavenumber of the absorption bands characteristic of dextran, as seen in
the pure and different concentrations coating the surface of MNPs.
Band location (cm-1)

[Dextran]
(Weight %)

υs (α-glucopyranose)

100

907

1019

1152

1279

1373

0.2

917

1019

1152

1328

1386

0.5

917

1019

1152

1328

1386

1.0

917

1019

1152

1328

1386

2.0

917

1019

1152

1328

1386

υs (C-O)

υs (C-H)
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Figure 26: FTIR spectra of pure dextran and different concentrations of dextran
coatings onto MNPs.
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Figure 27: Diagrammatic representation of the interaction between dextran functional
groups and iron ions of MNPs to form D-MNPs.
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3.2.2. TGA analysis of coated MNPs
Pure MNPs showed an average weight loss of 14%, as was previously shown
in Figure 16. This was attributed to the removal of water that was physically
adsorbed onto the surfaces of the NPs. Figures 28-30 show TGA curves of S-MNPs,
C-MNPs, and D-MNPs, respectively, as a function of the concentration of each of
the organic compounds initially added to the preparation reaction medium. Weight
loss of pure organic coating has been added to each of these figures for comparison.
SDS shows a major single step weight loss at a temperature of 180 ºC, which
denotes its degradation; Figure 28. This process increases until it levels off at a
temperature of 470ºC with an overall weight loss of 75.3% where SDS was
completely degraded. Pure chitosan shows an overall weight loss of 80% took place
after heating it to 600oC; Figure 29. This weight loss takes place over two stages,
where the first loss around 100oC and is attributed to the removal of physically and
chemically adsorbed water. This was followed by a major weight loss around 300°C
due to the degradation of chitosan that takes place through thermal and oxidative
decomposition [192].
Pure dextran, on the other hand, shows an initial weight loss at 100-150 ºC,
and is attributed to the removal of physically and chemically adsorbed water,
accounting for 10% of total weight loss. This was followed by a major weight loss
around 300°C that corresponds to the degradation of the polysaccharide dextran
chains; Figure 30. The overall weight loss at the end of heating of pure dextran
amounted to 92% due to the complete burn out of dextran [196].
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Figure 28: TGA analysis of MNPs coated with various concentrations of SDS. Insert:
TGA pattern of pure SDS.
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Figure 29: TGA analysis of MNPs coated with various concentrations of chitosan.
Insert: TGA pattern of pure chitosan.
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Figure 30: TGA analysis of MNPs coated with various concentrations of dextran.
Insert: TGA pattern of pure dextran.
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With the presence of these organic compounds as coatings onto the surfaces
of MNPs, TGA thermograms showed variable behaviour based on the type of coating
and its concentration that was initially added during preparation. Figure 28 indicates
that all S-MNPs showed two steps of weight loss; an initial step that started at a
temperature slightly below 100 °C, and a second step that started at a temperature
close to 200 °C. The first step is related to the evaporation of physically and
chemically attached water, while the second step is related to the degradation of the
SDS coating the MNPs. These results confirm the presence of SDS as a coating on
the surface of the prepared MNPs, as was previously shown in the FTIR spectra of
these samples in Figure 22. These findings also confirm the presence of multi-layers
of SDS coating the MNPs on which water was adsorbed.
Similarly, TGA thermograms of C-MNPs showed in Figure 29 indicated the
presence of two stages of weight loss. The first event of weight loss accounts for the
evaporation of physically and chemically adsorbed water; around 100oC, while the
second event took place at 300±10oC and is attributed to the degradation of chitosan
linked onto the surfaces of the MNPs.
D-MNPs showed similar pattern, where two stages of weight loss were also
observed; Figure 30. The first weight loss took place at 100-200oC, and is attributed
to the evaporation of physically and chemically adsorbed water molecules. The
second step, on the other hand, appeared at 250±100oC, with a higher temperature
achieved in samples containing higher concentration of dextran. In addition to these
events, a third event was observed around 500±50oC, which was slightly evident in
the TGA thermogram of pure dextran. This event appeared in an increasing manner
in the thermograms of samples containing ≥ 0.5 weight % of dextran, and could be
attributed to a delayed degradation of dextran-bonded MNPs. In addition, the overall
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early degradation of dextran coatings, as compared to pure dextran could be
attributed to the effect of MNPs in catalyzing the thermal decomposition of dextran,
which was previously reported in the literature [196].
Figure 31 shows a detailed analysis of the removal of water and organic
coating from the surfaces of the MNPs during their TGA analysis. These data were
derived from the TGA thermogarms in Figure 28-30. In the absence of organic
coatings, the weight loss is related to water only. As the concentration of the organic
coating was increased, a pronounced decrease in the weight loss owing to water was
observed and a consequent increase in the weight loss owing to the organic coating
was observed. This behavior continued up to 0.5% of SDS. As the percentage of SDS
was increased to 1%, its contribution to the overall weight loss was decreased with a
subsequent increase in the contribution of water to the overall weight loss; Figure
31a. The same criterion was also observed when 2% of SDS was initially added.
Figure 31b shows, on the other hand, that the amount of water adsorbed onto
the MNPs was largely reduced by the presence of chitosan, and that this amount
slightly decreased concurrently with the increase of concentration of chitosan
initially added to the system. The decrease in the slope between 1 and 2% chitosan as
compared with lower percentages of chitosan may indicate a relative decrease in the
affinity of the MNPs towards further addition of chitosan on their surfaces after 1%
concentration.
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Figure 31: A detailed TGA analysis of the removal of water and organic coatings
from the surfaces of the MNPs. a) SDS, b) chitosan and c) dextran.
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In the presence of dextran as a coating, a similar pattern was observed where
the amount of adsorbed water was highly reduced as the MNPs coated with dextran;
Figure 31c. As the concentration of dextran increased up to 1% the amount of water
decreased. This was followed by a slight addition of dextran onto the MNPs surfaces
from 1 to 2% as compared to lower dextran concentrations. This indicates the
decreased affinity of MNPs towards further addition of dextran on their surfaces after
1% concentration.
These results suggest that at SDS percentages above 0.5 %, its molecules
detach from the coating and are replaced by water. Detachment of adsorbed
molecules takes place when these molecules are weakly bonded to the substrate, i.e.
the MNPs. This indicates that the desorbed molecules are in the outermost layer of
SDS coating the MNPs. It should be mentioned that the primary layers are
thermodynamically known to strongly bond to the underlying substrate, whereas this
bonding decreases in strength for molecules in the external layers of the coating. The
same concept could be applied to the first layers of chitosan and dextran, which are
directly bonded to the underlying MNPs’ surfaces, as was explained in the previous
section; FTIR analysis of coated MNPs.
In the presence of chitosan and dextran, a possible increase in the thickness of
the chitosan coating layer was observed, and could be attributed to the development
of intermolecular forces, such as H-bonding and dispersion forces, amongst chitosan
molecules and dextran molecules in their coatings, respectively. In all cases, the first
layer(s) of organic coatings are secondarily covered with an external hydrated layer
through H-bonding. These findings explains the removal of water, as a first event,
from the surfaces of the organic-coated NPs, followed by the removal of the organic
coating, as shown in the TGA thermograms in Figures 28-30. Based on these
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discussions, a diagram showing the possible construction of coatings onto MNPs is
given in Figure 32.

Figure 32: Diagrammatic representation of the possible construction of water and
organic coatings onto the surface of MNPs.
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3.2.3. Morphology of coated MNPs
TEM micrographs of coated MNPs are shown in Figure 33. Neat MNPs were
previously shown in Figure 19b as spherical in shape, uniform in size and with an
average particle size of around 25 nm. In the presence of organic coatings in the
reaction medium, NPs maintained their shape and size distribution, but an overall
decrease in the particle size of the NPs was observed. This decrease was shown to
increase with increasing the concentration of the organic coating initially added to
the reaction medium; Figure 34. The lowest sizes of coated NPs achieved were 9,
10, and 10 nm when 2 weight % of SDS, chitosan or dextran, respectively, were
added to reaction medium during the precipitation of MNPs. These results confirms
the role of these organic compounds as capping agents that limited the size of MNPs
nuclei formed during precipitation in the aqueous medium. It is also evident that the
size of particles could be controlled by adjusting the type and concentration of the
organic material added during the formation of MNPs.
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Figure 33: TEM micrographs of MNPs coated with 0.2% of different organic
coatings. a) SDS, b) chitosan and c) dextran.
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Figure 34: Average particle size distribution of neat MNPs and MNPs coated with
different concentrations of organic coating materials. a) SDS, b) chitosan and c)
dextran.
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3.2.4. N2 adsorption and pore size distribution of coated MNPs
Organic-coated MNPs were subjected to N2-adsorption measurements to
assess their surface area, pore size and pore size distribution. These measurements
also provide information about the texture and topography of the NPs, especially if
their ultimate applications require special surface characteristics.
Figure 35 shows adsorption-desorption hysteresis of MNPs coated with
different concentrations of SDS, chitosan and dextran. All samples showed hysteresis
loops of type IV where the lower curve represents the adsorption of N2 gas on the
surfaces of the NPs, while the upper curve represents the progressive withdrawal, i.e.
desorption, of the adsorbed N2 gas [192]. As a result of these experiments, and
applying the BJH method of calculations, pore size distribution in each of the
examined MNPs systems was calculated. Results are shown in Figure 36. It should
be mentioned that these measurements are usually carried out on dry samples, where
NPs tend to agglomerate as a result of their magnetic characteristics in addition to
possible intermolecular forces between the organic-coated NPs.
Figure 36a indicates that NPs coated with 0.2% SDS appear to have
macroporosity with a larger pore volume of 150 nm, which is a reflection of the
larger particle size of these particles. By increasing the concentration of SDS, all
samples showed the presence of mesoporosity as a sole type of porosity. In the
presence of chitosan and dextran, all samples showed the presence of mesoporosity
with a unified monodisperse pore size distribution; Figure36b,c. Comparing the
results of adsorption isotherms and pore size distribution curves of organic-coated
MNPs with those in pure MNPs, indicates that the mesoporosity of the neat MNPs
aggregates is maintained even after coating with various concentrations of SDS,
chitosan and dextran. Both monodispersity in particle size and mesoporosity in these
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agglomerates are considered advantageous if these coated NPs are to be used as drug
delivery vehicles or adsorbents or catalysts for various chemical reactions with
potential environmental importance [179].
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Figure 35: Adsorption-desorption hysteresis of MNPs coated with different
concentrations of organic coating materials. a) SDS, b) chitosan and c) dextran.
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Figure 36: Pore size distribution of MNPs coated with different concentrations of
organic coating materials. a) SDS, b) chitosan and c) dextran.
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3.2.5. Magnetic properties of coated MNPs
The presence of an organic coating onto the surfaces of MNPs provides more
advantages to the NPs where the newly established surface functionality could be
used to immobilize other reagents to be used in drug delivery applications. However,
increased thickness of the coating might lead to a decrease in the magnetic properties
of the NPs, which is expected to decrease their potential for biomedical applications.
Therefore, the effect of varying the concentration of organic coatings on the
magnetic properties of the coated MNPs was investigated using a common VSM
instrument.
Results are shown in Figure 37, where magnetization was measured as a
function of the applied magnetic field at room temperature (300K). Neat MNPs and
NPs coated with 0.2 and 1.0 weight % coating were selected for these measurements
and for comparison. All Magnetization curves exhibited a typical behaviour of an
ideal superparamagnetic material with zero coercivity and zero remanence. This is
also confirmed with the fact that the average particle size of the neat and coated
MNPs is below 30 nm, which is considered a maximum threshold for
superparamagnetic character [197].
The superparamagnetic behaviour means the MNPs are a single-domain core
and the magnetization at room temperature is reduced to zero, but when an external
field is applied, the magnetic moments align with the field having magnetic field.
Non-coated MNPs showed a saturation magnetization (Ms) of 25.9 emu/g. The
presence of SDS as a coating onto the MNPs surprisingly resulted in an increase in
the magnetization of the coated NPs. The NPs coated with 0.2 weight % SDS
showed a magnetization of 50 emu/g, while increasing the SDS coating
concentration to 1.0 weight % showed a magnetization of 38 emu/g; Figure 37a.
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The increase in magnetization with the presence of SDS could be related to
the surface charges of the ionic SDS groups on the coating. Increasing the
concentration of SDS results in the formation of multilayers of SDS coating, which
might decrease the surface charge as a result of the interlocking between the SDS
molecules in the coating with increased thickness. This behaviour was not observed
in the magnetization of chitosan and dextran-coated MNPs; Figure 37b,c.
The presence of chitosan and dextran coatings with variable weight
percentages showed a range of magnetization of 7.0 - 21.3 emu/g. This could be
related to the charge neutrality of the chitosan and dextran molecules. It was
observed that the presence of chitosan and dextran resulted in a decrease in the
particle size of the coated MNPs, the development of a non-magentic organic coating
on the surfaces of these NPs in the presence of chitosan could be considered the main
reason for the decrease in magnetization. This is also a common phenomenon in
coated MNPs [173, 193].
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Figure 37: Magnetization of neat MNPs and MNPs coated with different concentrations
of organic coating materials. a) SDS, b) chitosan and c) dextran.
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3.3. Selection of organic-coated MNPs
Based on the previous results, MNPs coated with 1% by weight of dextran
were selected to be further functionalized for drug delivery objectives. These were
selected based on the following criteria:
1) Dextran is biocompatible and biodegradable.
2) Chemical Structure of dextran provides sites for further functionalization.
3) Dextran is a naturally occurring polysaccharide that can provide steric
hindrance for further stabilization of the NPs in aqueous media.
4) Average size according to TEM was around 14 nm, which is reasonable for
drug delivery applications [88].
5) Washing the extra unattached dextran was much easier than chitosan and
SDS, during preparation.
In order to increase the yield of D-MNPs while maintaining the phase purity
and monodispersity of the NPs, preparation of the dextran-coated MNPs was further
modified and optimized. In the modified procedure, MNPs were pre-formed from
more concentrated Fe2+ and Fe3+ solutions, MNPs were post-coated with 1% dextran.
Starting iron solutions were 1.2M Fe2+ and 2.4M Fe3+. After precipitation of the
MNPs in a highly alkaline NaOH solution, they were soaked at a temperature of
60ºC for 38 hrs. MNPs suspensions were then centrifuged and subjected to
successive decantation/centrifugation using sterile de-ionized water. Solutions
containing suspended MNPs were separated by centrifuge, to be coated by dextran.
A highly alkaline solution of NaOH containing 1 weight % dextran was used, so that
the weight ratio of MNPs-to-dextran was 3:1. Extra un-attached dextran was
removed by successive centrifugation and decantation, and was confirmed by
Benedict’s test. It should be mentioned that all preparation were carried out under
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sterile conditions in a biological hood using sterile equipments and reagents. To
confirm phase composition, D-MNPs were separated by centrifuge, dried and
characterized using FTIR and TGA techniques.
Figure 38 shows FTIR of pure MNPs (0.0 % coating) and the D-MNPs
(1.0% coating). Bands representing pure MNPs Fe-O bonds were appeared at 429,
561 and 618 cm-1 in the spectrum of pure MNPs. These bands were shifted to at 428,
571 and 619 cm-1 bands, respectively, in the FTIR spectrum of 1% D-MNPs. In
addition, the presence of dextran as a coating was confirmed by its bands at 1010 and
1150 cm-1 for C-O group, and 1342 cm-1 for C-H group in D-MNPs.
Moreover, the presence of dextran as a coating onto MNPs was confirmed by
TGA analysis; Figure 39, where weight loss of D-MNPS indicated the presence of
dextran as a coating. This was evident through the major weight loss around 200 oC,
and the minor weight loss around 450oC, which were attributed to the degradation of
dextran. It should be mentioned that TEM analysis of these NPs showed an average
particle size of 16 nm with and without the coating, which may indicate the presence
of a thin coating of dextran onto the MNPs.
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Figure 38: FTIR of pure MNPs and the D-MNPs.
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Figure 39: TGA of pure MNPs and the D-MNPs.
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3.4. Crocin loading characterization
Crocin was chemically conjugated, via succinic anhydride as a cross linker,
onto the surface of functionalized D-MNPs synthesized in this study. Results of three
formulations are presented in this dissertation. Each formulation was numbered
according to the crocin concentration that was used in vitro or in vivo experiments
(Table 9). The iron concentration used, was considered safe based on our previous
studies.
The remained attached crocin was 70 mg/ml in 3 mg/ml formulation, 33
mg/ml attached crocin was in 2 mg/ml formulation, and in 4 mg/ml formulation the
attached crocin was 40 mg/ml (Table 9 and Figure 40). The difference in attached
crocin might be because of the difference in the percentage of the coating with
dextran among the NPs them self.

Table 9: Analysis of crocin and iron content in different D-MNPs formulations.

Tested crocin
concentration

3 mg/ml
(in vitro)
2 mg/ml =
11 mg/kg
(in vivo)
4 mg/ml =
22 mg/kg
(in vivo)

Initial crocin
concentration
(mg/ml)

Crocin
loading
efficiency
(%)

Attached
crocin
concentration
(mg/ml)

Non-toxic Fe
concentration
(NPs with and
without crocin)

100

70

70

0.09mg/ml9µg/100µl

100

33

33

17mg/kg0.3mg/100µl

50

80

40

17mg/kg0.3mg/100µl
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The results of FT-IR spectrum of pure crocin showed the bands at 1515 and
1631 cm-1 due to C=C. Also it shows 1697 cm-1 because of C=O [153], 2933 cm-1
band caused by C-H and the broad stretch between 3262 and 3441 cm-1 corresponds
to the presence of O-H groups [198]. FTIR spectrum of D-MNPs with crocin shows
the unique bands of C=C at 1534 and 1637 cm-1 which is only present in crocin,
confirming the successful addition of crocin in the D-MNPs as seen in Figure 41.
The synthesis reaction of crocin-loaded D-MNPs was as follows. Free
hydroxyl groups on dextran reacted with succinic anhydride to form covalent ester
bonds and a free carboxylic acid. The latter is used to link the hydroxyl group of
crocin via esterification. Succinic anhydride is an organic compound with the
molecular formula C4H4O3 (Figure 42). It can form a strong ester bonds between
itself and crocin or dextran as mentioned earlier. These bonds can break specifically
in acidic environment as in cancer site to release crocin in active form, dextran and
succinic acid. EDCI was used during the esterification reaction as the coupling
reagent to activate succinic acid enabling crocin to bind. It did not interfere in the
chemical structure and its end product (urea derivative) can be washed out easily by
water Figure 42.
Figure 43 shows the TEM of D-MNPs and 4 mg/ml crocin-loaded D-MNPs
as representative formulation. The size of synthesized crocin conjugated D-MNPs by
esterification process was uniform and monodisperse. The average diameter of DMNPs with and without crocin was 16 nm, indicating that the addition of dextran and
crocin layers were very thin and did not affect the main core size of MNPs.
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Figure 40: UV-Visible spectral measurements of crocin, D-MNPs and 4 mg/ml
crocin-loaded D-MNPs.
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Figure 41: FTIR of crocin, D-MNPs and 4 mg/ml crocin-loaded D-MNPs.
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Figure 42: Schematic representation of chemical synthesis of crocin-loaded DMNPs.
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Figure 43: TEM micrographs of (a) D-MNPs and (b) 4 mg/ml crocin-loaded
D-MNPs. Insets: individual round shaped MNP.
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3.5. In vitro release of crocin
The cumulative release of crocin from the prepared D-MNPs carrier was
investigated at pH values of 5.5 and 7.4 at the physiological temperature of 37 ºC.
The cumulative drug release was expressed as the percent of de-attached crocin from
D-MNPs and released to the surrounding aqueous media as a function of time. The
drug release activity depends on many characteristics of the NPs, such as surface
characteristics and forces of interaction between crocin and the underlying D-MNPs.
The in vitro drug release behaviour of crocin loaded D-MNPs was studied in PBS at
pH 7.4 and a temperature of 37ºC to maintain the experimental condition similar to
the physiologic conditions. The tumour tissue has acidic nature with pH 5-6
compared to the healthy tissues at pH 7.4 [168, 199, 200], because of that the release
study was investigated at pH 5.5 at temperature of 37ºC to understand the release
mechanism in cancer site.
Figure 44 shows the percentage of cumulative release of crocin from 2 and 4
mg/ml crocin loaded D-MNPs formulations and both with 3 mg Fe/ml. The release
behaviour of 2 mg/ml crocin loaded D-MNPs at 0.0 hr was 16% at pH 5.5, whereas
at pH 7.4 it showed a percent release of 4%. The release increased as the time
increased to reach 47 % and 38 % at pH 5.5 and 7.4, respectively after 15 day.
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Figure 44: Release profiles of crocin from the prepared two formulations. a) 2 mg/ml
and b) 4 mg/ml crocin conjugated D-MNPs with 3 mg Fe/ml in PBS at pH 5.5 and
7.4.
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On another hand, there was initial burst release in 4 mg/ml crocin loaded DMNPs with 33% at pH 5.5 compared with 9% at pH7.4. The release rate at 5.5 pH
increased to reach 46% in the first 4 hrs. Then it was accelerated constantly as the
time prolonged to reach 88% in day 15th and 92% in day 17th. In addition, the crocin
release at pH 7.4 was lower than 5.5. In the first 4 hrs it was 21%, and then the
release was increased regularly till day 15th to be 75%. But it started to increase
slowly to reach 76% after 17 days. In General, the release behaviour in 4 mg/ml
crocin loaded D-MNPs were faster than 2 mg/ml formulation.
In this study crocin release in both buffer solutions showed sustained release
behaviour with time in both formulations. Release of crocin might be attributed to
the slow cleavage or hydrolysis of hydrogen bond between crocin and cross linker
that was directly attached to the D-MNPs. A maximum percentage of crocin release
was 92% and was obtained under acidic conditions (pH 5.5) compared to 76% in
physiological conditions (pH 7.4) after 17 days. This difference in release is
significant (P = 0.0127< 0.05, student t-test). The higher percentage of release was
obtained due to the increase in hydrolysis of carboxylic esters linkage between crocin
and succinic acid that bound to D-MNPs. After hydrolysis each compound returned
to its original structure producing; crocin, succinic anhydride, and dextran attached to
MNPs, while the MNPs might degrade to free iron that will bind to ferritin protein in
the cells.
Because of leaky and pre-mature blood vessels of cancer tissues, the chance
of crocin loaded D-MNPs to accumulate inside these tissues by passive targeting will
be higher than normal tissues. Leading to an increase in the concentration of crocin
loaded D-MNPs to 10-100 times higher in cancer tissues within 1-2 days compared

140

to normal ones. Consequently, this will increase the hydrolysis and release of crocin
in cancer tissues [90, 201-203].
The current results are consistent with the findings of previous researchers,
who demonstrated that acidic conditions accelerate the cleavage of the bonds
connecting the linker to the crocin and underlying D-MNPs, and the passive targeting
can accumulate the NPs in tumour tissues more than normal one [168, 200].
3.6. In vitro cytotoxicity
In this study, the human hepatocellular carcinoma cell line HepG2 was
selected as a model of cancer cells for in vitro experiments. Cell proliferation and
viability were evaluated by MTT assay. HepG2 cells were incubated for 72hrs with 9
different concentrations of crocin including 0.025, 0.05, 0.5, 3, 5, 8, 10, 15 or 20
mg/ml as well as crocin-free control. Compared to control group, microscopic
examination of crocin treated cells showed morphological changes such as rounding
of cells, reduced cytoplasm, cell shrinkage and pyknotic nuclei, suggesting apoptosis
induction [68, 204].
Similar apoptotic-related changes have been reported in HeLa cells after
being treated with crocin. IC50 of crocin-treated HeLa cells was 3 mg/ml (3mM)
18hrs post incubation. Crocin was also found to be more effective than other saffron
bioactive ingredients such as crocetin and safranal [205].
MTT assay results showed that crocin decreased the cell viability in a dosedependent manner. There were significant reductions (P ≤ 0.001) from 3 to 20 mg/ml
concentrations compared with control as in Figure 45. The IC50 of crocin was around
6 mg/ml, which is equivalent to 6 mM.
Noureini et al. reported that crocin has a significant cell viability inhibitory
impact in both dose- and time-dependent manners on HepG2 cells. This antiproliferative effect was proposed to be due to the telomerase inhibition that resulted
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from down regulating hTERT (catalytic subunit of telomerase gene) [206]. Studies
have shown that the crocin has the potential to inhibit growth of different types of
cancer cell lines. The IC50 of crocin on HL-60 leukemic cells was 2 µM (µg/ml).
Other cell lines including K562, HeLa, HCT-116 and HT-29, had IC50 of 0.4, 3, 10
and 1 mg/ ml, respectively [67, 207].
Sun et al. suggested that crocin (0.625-5 mg/ml) reduced cell proliferation in
human leukemia HL-60 cell line, and caused apoptosis and cell cycle arrest at G0/G1
phase, in concentration- and time-dependent manners [208]. These results are in
agreement with the investigation of Hoshyar et al. who also found that crocin
triggered the apoptosis through increasing the Bax/Bcl-2 ratio and caspase activation
in human gastric adenocarcinoma, AGS cells [209].
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Figure 45: MTT cell viability assay of HepG2 cells, which were incubated with
different concentrations of crocin for 72 hrs. All the values are expressed as mean
±SEM; ***P ≤ 0.001.
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Crocin also inhibited the proliferation of human tongue squamous cell
carcinoma cell line, Tca8113, through reducing the nucleic acid synthesis and
inducing apoptosis [210]. It also induced apoptosis and G1-phase cell cycle arrest in
a human pancreatic cancer cell line, BxPC-3, and colorectal cell line, HCT-116,
while decreasing cell viability in dose-and time-dependent manners [207, 211].
However, crocin has no toxic effects on normal cells such as human normal
fibroblast skin cells, HFSF-PI3 [67, 209].
MTT assay was then used to study the effect of D-MNPs on viability of
HepG2 cells. Different concentration of iron contents of applied D-MNPs were
incubated with HepG2 cells for 72 hrs and the corresponding cell viability were
plotted in Figure 46. The cell viability decreased as the iron concentration increased
in a concentration-dependent manner. There was no significant inhibition at 0.05
mg/ml compared to the control. The cell viability was obtained at 90 to 60% in a
broad concentration range of 0.05 mg/ml to 0.1 mg/ml. This demonstrated that the
MNPs carrier coated with dextran had good biocompatibility due to its sugar
components. The increase in cytotoxicity might be because of some MNPs lost their
dextran coating, consequently exposing MNPs to the cells [200].
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Figure 46: Cytotoxicity of different iron concentrations in D-MNPs on HepG2 cells
after 72 hrs. All values are expressed as mean ±SEM; **P ≤ 0.01, ***P ≤ 0.001.
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Kumar et al. demonstrated that the cell viability of human breast cancer cell
line MCF-7 cells was obtained at 90 to 78% in concentration range of 0.01-0.1
mg/ml for 24 hrs compared with control cells. They also concluded that the MNPs
coated with dextran had good biocompatibility [200]. In other study, a range of
MNPs with varying physico-chemical properties primarily demonstrated low
cytotoxicity at doses of 0.1 mg/ml or higher [3]. Therefore, 0.09 mg/ml (9 µg/100µl)
iron-content D-MNPs were loaded with crocin for further in vitro studies.
MTT assay at 72 hrs of HepG2 cells was also used to evaluate the anti-cancer
effect of 3 mg/ml crocin-loaded D-MNPs with 0.09 mg Fe/ ml and compare it with
control, 3 mg/ml crocin or D-MNPs with 0.09 mg Fe/ml as in Figure 47. Three
mg/ml crocin was selected from the previous free crocin screening to test if crocinloaded D-MNPs enhance the crocin-inhibitory effect over free crocin by reduce the
proliferation of HepG2 cells. Inverted microscope observations showed that the cell
viability of the HepG2 incubated with free crocin and crocin-loaded D-MNPs
decreased as incubation time increased from 24 to 72 hrs. However, D-MNPs had no
significant effect on the cell viability compared to control. Villanueva et al. revealed
that the viability of cell culture of D-MNPs with HeLa cells at 24 hrs was not
significantly affected by the presence of the NPs compared to control [212].
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Figure 47: Cytotoxicity effects of media alone as a control, 3 mg/ml crocin alone, DMNPs with 0.09 mg Fe/ml and 3 mg/ml crocin-loaded D-MNPs with 0.09 mg Fe/ml
on HepG2 cells. Values are expressed as mean ±SEM; *P ≤ 0.05, **P ≤ 0.01.
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In the present study, MTT assay at 72 hrs incubation of HepG2 cells resulted
in crocin conjugated D-MNPs significantly decreased (P ≤ 0.01) the cell viability to
65% compared to non-significant inhibitions 82% of free crocin, and 87% of DMNPs and all compared to control. The decrease in cell viability associated with DMNPs group might be due to the degradation of dextran and exposure of MNPs to
the cells. There was significant decrease (*P ≤ 0.05) between crocin-loaded D-MNPs
and D-MNPs groups. However, there was no significant difference in cell viability
between D-MNPs and control groups.
The D-MNPs either alone or with crocin were stable in the DMEM medium
as well as in the deionized or auto-cleaved water (storage solution) during the time of
testing and after weeks of storage, indicating that these NPs have stabilizing shell
which not only decrease agglomeration but also protect them from external factors.
A carrier like D-MNPs has been shown to increase the uptake by cancer cells
via adsorption, fusion, and endocytosis [90, 212, 213]. The increased toxicity of the
crocin coated D-MNPs on HepG2 cells might also be due to the anti-proliferation
effect of crocin that might be released as shown earlier in the release study (Figure
44). Nanoliposomes containing crocin have been shown to improve cytotoxic and
apoptotic properties of crocin on HeLa and MCF-7 cancer cell lines compared to free
crocin. No cytotoxic effects were however reported on the non-malignant mouse
fibroblast cell line L929 [67, 214]. To confirm the cytotoxic effect of the crocinloaded D-MNPs, further in vivo study was performed.
3.7. In vivo anti-tumour efficacy
Balb/c mice strain was chosen for this study as it has been used as a model
for carcinogenicity in other studies [42, 46, 48, 49, 215-217] and it is relatively
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sensitive to the induction of hepatic tumors by chemical carcinogens such as DEN
[48].
No previous study has been used multiple injections of DEN to induce preneoplastic foci or HCC in pre-weaning Balb/c mice of 3 weeks old. So, in this study
we are characterizing a modified pre-cancerous mice model that can be produced in
two months only. This model also mimics the human pre-cancerous procedure, as it
is a multistep model where cycles of de-generation and re-generation might activate
pre-neoplastic transformations. The progression of early dysplastic lesions to
malignant tumours is associated with an increased occurrence of genomic alterations
[17, 51].
The younger the mice are the faster HCC will develop because of the high
hepatocytes proliferation rates of young animals. Also, HCC deveolps in male more
than female is because of the stimulating effect of androgens and the inhibitory effect
of estrogens on hepatocarcinogenesis [13, 16, 17, 41].
3.7.1. General Observation, Body and Liver Weight
In this study, 50 mg/kg DEN was used to induce hepatic carcinogenesis in 3weeks old pre-weaning male Balb/c mice. DEN administration caused reduction in
the body and liver weights as shown in DEN-induced group compared to normal
group as in Figure 48. This reduction in body and liver weights was because of the
cytotoxic effect induced by DEN. Some animals could not tolerate DEN induced
cytotoxic effect and died. DEN exposure affects liver at two stages: initially it
reduces the hepatocytes cell proliferation, then cell proliferation and DNA synthesis
increase to ultimately form pre-cancerous lesions and cancer. Such initial depression
in cell proliferation and DNA synthesis was combined with amount of cell damage or
death that was enough to cause some animal to die, before the regenerative response
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was triggered. This reduction in the hepatocytes proliferation might decrease the
overall body and liver weights in spite of some pre-cancerous changes was taking
place in the liver as confirmed by IHC studies section later [31].
In addition, cell proliferation reduction of hepatocytes was associated with
the initial interval of cytotoxicity that was reported by Rajewsky et al. in 1966. Male
rats were exposed to 5 mg/kg DEN per day in drinking water for 11 weeks. The
initial reduction of hepatocytes proliferation was for 3-5 days. After this period, cell
proliferation increased to 2-3 times [41]. Figure 48 shows the body and liver weights
in 11 and 22 mg/kg crocin-loaded D-MNPs with 17 mg Fe/kg treated groups
recovered and increased compared to DEN-induced or free crocin groups. Indicating
better effectiveness of crocin-loaded D-MNPs than free crocin. Crocin-conjugated
PEGylated nanoliposomes have been shown to increase the weight of Balb/c mice
with C26 tumor when compared with free crocin [218].
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Figure 48: Body and liver weights of Balb/c mice treated with different
treatments. a) Body and b) liver weights of normal, DEN injected mice treated
with saline (DEN-induced group), 11 mg/kg crocin, and 11 mg/kg crocin-loaded
D-MNPs with 17 mg Fe/kg. c) Body and d) liver weights of normal, DEN injected
mice treated with saline (DEN-induced group), 22 mg/kg crocin, and 22 mg/kg
crocin-loaded D-MNPs with 17 mg Fe/kg. Values are expressed as mean ±SEM;
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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3.7.2. Histopathological examination
Figures 49 and 50 show normal structure and histology of liver as seen in the
normal group of mice. The liver is divided histologically into lobules; each lobule
appears hexagonal in shape. The center of the lobule include the central vein,
however the portal triads are located at the periphery. The portal triad consists of
branches of hepatic artery, portal vein, and bile duct. It also includes lymphatic
vessels. The hepatocytes appear mono or bi-nuclear with round and centrally located
nuclei. Hepatocytes are also arranged in single-cell thick plates that radiate out from
the central vein. These plates are separated or surrounded by vascular sinusoids [10].
In the animal model that has been developed in this study, no gross or
macroscopic tumor was observed in the livers of any DEN injected group. However,
microscopic histological examination of livers of mice in DEN-induced group
showed clear pre-neoplastic changes including large and small cell dysplasia, such as
altered hepatocellular foci (AHF), and accumulation of lymphocytes, intrahepatic
bile ducts and oval cells. AHF were also considered by some researchers as islands
of cellular alteration [42, 217, 219].
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Figure 49: Diagrammatic representation of liver normal structure and blood flow.
Hepatic lobules of liver are represented by hexagonal hepatocytes cells structure
and surrounded by portal triads at the corners. CV; central vein.
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Figure 50: Liver’s normal
histology (H&E stain). a)
Portal triad area consists of
branch of portal vein and bile
duct, scale bar = 100µm, b)
central vein and hepatocytes,
scale bar = 100µm, and c)
hepatocytes are surrounded by
sinusoids, endothelial and
kupffer cells, scale bar =
50µm.
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Other changes were also determined such as hepatocytes with vacuolated
nucleus, nuclear pleomorphism, multi-nucleation, mitotic activity, increased
proliferative index, giant cells and hepatic cytolysis (Figure 51). Apoptotic bodies
were detected in the portal area, suggesting that apoptosis was contributory to clonal
growth via removal of adjacent normal cells [42, 217, 219]. In this study, there were
also other features of cells undergoing apoptosis and characterized by cell shrinkage,
membrane blebbing, chromatin condensation and nuclear fragmentation. Similar
features were reported in other DEN models studies [220].
Similar to tumorigenesis in other organs, hepatocarcinogenesis in humans and
rodents is a multistep process characterized by the development of cellular
intermediates that progressively cause genetic alterations that regulate transformation
of normal cells into malignant cells. AHF is one of the major cellular alterations
[219] that are known to occur in consequence of liver injury, and are considered to
be one of the pre-neoplastic predictive markers associated with HCC. AHF can be
categorized into basophilic, eosinophilic, clear, vacuolated, or mixed [221-223].
In the present study, most of the liver foci in mice of the DEN-induced group
were identified to be consisted of mixed of basophilic, vacuolated and clear cells
(Figure 51). The distribution of all types appeared to be at random with respect to
the hepatic lobule. AHF are generally distinguished as circular areas of hepatocytes
with altered staining properties. Basophilic AHF are composed of cells that are
usually smaller than adjacent normal hepatocytes. In vacuolated AHF, hepatocytes
are enlarged with large or small lipid vacuoles in the cytoplasm and mostly central
nuclei due to displacement by vacuoles. The cytoplasm of vacuolated AHF showed
patchy cytoplasmic staining as seen in Figure 51. Cells in clear AHF are normal
sized or enlarged with central, often hyperchromatic nuclei, and clear whitish
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cytoplasm that must be distinguished from vacuolated one by lack of cytoplasmic
lipid vacuoles. Hepatocytes in eosinophilic AHF are generally larger than normal
hepatocytes and have diffusely eosinophilic cytoplasm. The cytoplasm in
eosinophilic AHF varies from mild to intense. The mild eosinophilic foci were
difficult to distinguish in the staining from surrounding parenchyma.
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Figure 51: Formation of AHF in the liver of DEN-induced group. a) Mixed cell
AHF composed of basophilic, vacuolated and clear cells, scale bar = 500 µm, b)
vacuolated and clear cells, scale bar = 100 µm, c) cholangioma, lymoocytes
hyperplasia and apoptotic bodies, scale bar = 100 µm, d) cholangioma, scale bar
= 100 µm, e) vacuolated nuclei and the cell, scale bar = 50 µm, and f) mitotic
figure in Metaphase stage, scale bar = 50 µm.
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DEN is a carcinogenic chemical that is found in tobacco smoke, cured or
fried meals, cosmetics, agricultural chemicals and some pharmaceutical agents.
Previous studies have shown that DEN may induce carcinogenicity by several ways.
i) Alkylating DNA structures leading to the formation of mutagenic DNA adducts
[13, 16, 17, 33]. ii) Generating ROS that causes carcinogenesis by damaging DNA,
protein and lipid molecules [13, 16, 17, 33]. iii) Inducing mutations in H-ras protooncogene leading to unlimited cell division and, eventually, cancer development [13,
17, 35]. iv) Inducing over-expression of the Bcl-2 gene [17]. v) Stimulating the
proliferation of hepatic oval cells and bile duct cells leading to hyperplasia and the
formation of microscopic intrahepatic cholangioma [38, 39].
A previous study has utilized pre-weaning Balb/c mice strain where a single
dose DEN was used as initiator [216] followed by a promoter such as phenobarbital
[48] or partial hepatectomy [215] to accelerate growth of pre-neoplastic focal lesions
[42]. In the present study, pre-weaning Balb/c mice were injected with multiple
doses of DEN for two months which is considered a modified protocol to induce preneoplastic foci and cholangioma.
Similar pre-neoplastic cytological alterations that were observed in this study
were also observed in the transgenic mice model. Gillet et al. generated several lines
of transgenic mice that develop hepatocarcinoma in response to expression of wildtype SV40 early sequences, under the control of the regulatory sequences of human
anti-thrombin III gene (TAg mice, previously named ASV mice). As of second
month of life, transgenic livers are characterized by pre-neoplastic cytological
alterations, including anisocytosis, anisokaryosis, increased proliferative index, giant
cells and hepatic cytolysis. These pre-neoplastic foci become macroscopic from the
second month onward. But all animals die before the age of 7 months [219].
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In the combined treatment group of D-MNPs loaded with crocin at 11 mg/kg
and 22 mg/kg concentrations, there were reduction in the pre-neoplastic changes
compared to groups of DEN-induced or free crocin (Figures 52 and 53). The overall
pre-neoplastic reductions were better in 22 mg/kg than 11 mg/kg crocin-loaded DMNPs formulation, which might be because of high concentration of crocin. The
brown color in the combined treatment in Figure 53 indicated the presence of DMNPs that attached to the 11 mg/kg or 22 mg/kg crocin. To confirm the presence of
these NPs, Prussian blue stain was used with and without H&E stain.
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Figure 52: Histological examination of AHF arising in livers of Balb/c mice after
DEN administration and treated with 11 mg/kg or 22 mg/kg free crocin. a) Portal
area and b) central vein of 11 mg/kg crocin treated animals, each scale bar = 100
µm. c) Portal area and d) central vein of 22 mg/kg crocin treated animals, each
scale bar = 100 µm.
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Figure 53: Histological examination of AHF arising in livers of Balb/c mice post
DEN administration and treated with 11 mg/kg crocin-loaded D-MNPs or 22 mg/kg
crocin-loaded D-MNPs, both doses contained 17 mg Fe/kg. a) Portal area and b)
central vein of 11 mg/kg crocin-loaded D-MNPs treated animals, each scale bar =
100 µm. c) Portal area and d) central vein of 22 mg/kg crocin-loaded D-MNPs
treated animals, each scale bar = 100 µm. The arrow indicates presence of D-MNPs
loaded with 11 or 22 mg/kg crocin in liver tissues.
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3.7.3. Detection of D-MNPs in vivo
To confirm that the pre-neoplastic lesion size reduction correlated with MNPs
accumulation after 24 hrs of last i.v. injection, we used Prussian blue stain to analyze
MNPs in liver of normal and 22 mg/kg crocin-loaded D-MNPs contained 17 mg
Fe/kg as representative groups (Figure 54). Prussian blue staining showed more
MNPs accumulation in liver tissue, mostly in kupffer cells, treated with crocinloaded D-MNPs in the 2 formulations. However, NPs were neither observed in the
normal (Figure 54a), the DEN-induced nor in the free crocin groups (data not
shown).
Despite this widespread distribution of crocin-loaded D-MNPs in vivo, it
should be emphasized that we did not have any fatalities due to the blocking of blood
vessels at the MNPs dose used in this study. The size of D-MNPs with crocin is 16
nm which still is in the acceptable size range to be i.v. injected in the mice [3]. MNPs
in the size range 10-100 nm have been considered to be optimal for i.v.
administration. Particles more 100 nm and less than 10 nm are isolated by the spleen
or removed via renal clearance, respectively [3]. D-MNPs administration and its iron
oxide concentration used in this study caused neither adverse effects nor death to any
of the examined mice. Thus, the data suggest that D-MNPs are biocompatible and
adequate for biomedical experiments.
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Figure 54: Prussian blue staining of liver sections. a) Normal liver and b) liver
section of mouse treated with 22 mg/kg crocin-loaded D-MNPs, each scale bar = 100
µm.
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The bright blue clouds around D-MNPs clusters with crocin (Figure 55)
suggested free iron release from the clusters. The fate of D-MNPs following i.v.
administration will mainly be in liver and spleen as a filtration system, which also
confirmed by histological studies done by other researchers. Iron-release evidences
observed more in the liver tissue compared to spleen. The clusters of D-MNPs were
restricted to spleen red pulp. The primary function of red-pulp is to filter the blood
from various components and it includes granulocytes and macrophages [224]. While
white pulp mainly contains lymphocytes, such as T cells. Lacava et al. observed that
D-MNPs decrease in numbers throughout 6 months in liver and spleen of normal
mice [224]. In spite of the presence of D-MNPs in both liver and spleen tissues, no
damaged cells or any other alterations were observed in the investigated normal
tissues. Thus, D-MNPs have proven to be safe and they are currently used clinically
in different forms such as Feridex IV and Resovist [90, 91, 146].
Magnetic core may cause toxic effects to organisms if it was left directly
exposed to the cells. This may occur if weak bonding between dextran and MNPs
exist. Uncoated magnetic cores tend to aggregate and may lead to the precipitation
of MNPs that eventually block the blood vessels and kill the organism. Furthermore,
uncoated MNPs can induce genotoxicity via generation of ROS. Upon internalization
of MNPs into the cell, MNPs might degrade in the lysosomes by hydrolyzing
enzymes into free ferrous ions (Fe2+). These free ions might cross the mitochondrial
membrane and react with hydrogen peroxide and oxygen to produce highly reactive
hydroxyl radicals and ferric ions (Fe3+). The generated hydroxyl radicals can damage
DNA, proteins, polysaccharides and lipids. Thus, iron overload and its subsequent
homeostatic imbalance may have direct cellular responses including, but not limited
to, DNA damage, and inflammatory processes. Ensuring the surface coating of
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MNPs is therefore essential to prevent the release of toxic ions from magnetic core
[3, 213, 225].
It is also known that MNPs is one of the most iron oxide-based particles used
in vivo. That is because they are easily degraded and cleared from circulation by the
endogenous iron metabolic pathways. The released iron is normally metabolized in
the liver and subsequently used in the formation of red blood cells, bind to ferritin or
excreted via kidneys [3, 212, 213, 225]. In previous section of this study, both TGA
and FTIR analyses have been utilized to insure the presence of dextran as a coating
material. Also, the in vitro release study confirmed the release of crocin not dextran
at different conditions (Figure 44).
The distribution of MNPs localized in the liver tissue might indicate presence
of endosomes that could merge with lysosomes at later stage of endocytosis. MNPs
have already been reported inside endosomes around nucleus in the cytoplasm, but
not inside the nucleus of the cells [212]. Lysosomal enzymes might break the bond
between the crocin and the cross-linker attached to D-MNPs, and thus releasing the
crocin as its intact active structure. The D-MNPs entrapped by Kupffer cells
indicates an efficient elimination process of MNPs through phagocytosis in the mice
treated with NPs.
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Figure 55: Subcellular localization of 22 mg/kg crocin-loaded-DMNPs and
stained with Prussian blue. The tissues were counterstained with a) neutral red,
and b) H&E stain, each scale bar = 50µm. Crocin loaded-DMNPs are localized
in the cytoplasm. Red arrow: D-MNPs in hepatocytes, and Black arrow: DMNPs in Kupffer cells.
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Once in the bloodstream NPs are rapidly coated by components of the
circulation, such as plasma proteins in process known as opsonization. This process
is critical in determining the circumstance and the fate of the injected NPs. Normally;
opsonization makes the particles identifiable by the body’s major defense system, the
reticuloendothelial system [226]. It is a system of specialized cells that are
phagocytic and can be found in connective tissues area of the liver, spleen and lymph
nodes [90, 203, 212].

Kupffer cells and the macrophages of the spleen and

circulation play a critical role in the removal of opsonized particles. As a result, the
application of MNPs in vivo would require surface modification that would ensure
that particles are non-toxic, biocompatible and stable like hydrophilic compounds
[88, 92, 188, 227]. Hydrophilic compounds such as dextran polymer have been used
in this study, and dextran was shown to resist the opsonization process and to slowly
clear thus increasing the half-life of MNPs and the crocin.
The

leaky

nature

of

vasculatures

in

pre-neoplastic

and

tumor

microenvironment facilitates the extravasation of NPs (10–500 nm) from the blood
circulation and selective penetration into the cancer microenvironment. However, the
poor lymphatic drainage system helps them to be retained [228-230].
3.7.4. Immunohistochemistry studies
This section was designed to analyze the anti-cancer efficacy of free crocin
versus crocin-loaded D-MNPs on liver has pre-cancerous lesion in Balb/c mice.
Immunohistochemistry staining for GST-P was employed to identify the presence of
pre-neoplastic foci after DEN administration, which was followed by treatments with
saline (DEN-induced group), free crocin or crocin-loaded D-MNPs as detailed in
materials and methods section.
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3.7.4.1. GST-P expression
Glutathione S-transferases (GSTs) are a major group of phase II enzymes,
and among the most powerful cellular detoxifying systems. This family facilitates the
catalysis of thioether bonds between glutathione and electrophilic compounds
including carcinogens, drugs and a variety of products of cellular metabolism (both
endogenous and exogenous compounds). This family is grouped into six classes
according to the number of chromosome, Alpha (chromosome 6), Mu (chromosome
1), Omega (chromosome 10), Pi (chromosome 11), Theta (chromosome 22), and
Zeta (chromosome 14). There are both structural and functional redundancies
between isozyme family members.
GST-P form belongs to the Pi class of GSTs. GST-P was first identified in rat
placenta and was hence named the placental form. The GST-P in the rat is markedly
induced

in

pre-neoplastic

foci

and

nodules

induced

by

experimental

hepatocarcinogenesis [231, 232]. GST-P could be detected in a single cell as early as
2–3 days after the i.p. administration of DEN. This gene is expressed in response to
almost all of the chemical carcinogens, and can be found as a predominant protein in
other tumors like breast cancer [231-233].
GST-P levels in normal rat tissues including fetal, adult and regenerating
livers, and even in the placenta are very low compared to livers bearing preneoplastic foci [232]. This enzyme is not induced by the same eletrophilic
xenobiotics which induce the expression of other GST isozymes. The expression
patterns of GST-P is closely associated with the early stage of hepatocarcinogenesis
[231].
GST-P expression was estimated as the percentage of cells positively stained
by the antibody and detected by the DAB substrate (brownish color) in the cytoplasm
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and nucleus of the cells. Two months post DEN administration, the expression of
GST-P in DEN-induced group increased with strong intensity compared to the
normal group. Both tested formulations 11 and 22 mg/kg crocin-loaded D-MNPs had
more pre-neoplastic foci inhibition

compared to DEN-induced

or free crocin

(Figures 56 and 57) especially in 22 mg/kg crocin formulation.
The percentage of the GST-P positive foci was quantified from relative IHC
staining cells of pre-neoplastic foci in twenty fields per group. The quantification
analysis was performed using Image Pro 6 software, and was confirming the IHC
analysis. The percentage of expression of GST-P foci was significantly increased in
DEN-induced group (P ≤ 0.001) compared to normal group as in Figure 58.
Sheweita et al. demonstrated that DEN increased the activity of GSTs by 50% after 1
hr only of i.p. injection with 20 mg/kg in Balb/c mice [234]. Also Narumi et al.
reported that the expression of GST-P positive single hepatocytes appeared after the
initial DEN treatment with 12.5 mg/kg/day and their numbers increased as the
number of days of DEN administration increased to 14th days. GST-P positive minifoci existed on the 7th day of DEN post-treatment and increased prominently on the
14th day post-DEN treatment [235].
Amin et al. indicated that saffron-mediated reduction of nodular hepatocytes
that was associated by significant decrease in the number of GST-P positive foci
induced by DEN in rats [68]. On the other hand, the percentage of expression areas
in the combined treatment group crocin-attached D-MNPs in both 11 and 22 mg/kg
formulations were reduced compared to DEN-induced or free crocin groups (Figure
58). This might be because of the role of NPs as a carrier in improving the anticancer effects of crocin.
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Figure 56: Effects of 11 mg/kg crocin and its NP formulations on GST-P
expression in liver. a) Normal, b) DEN-induced, c) free 11 mg/kg crocin, and d)
11 mg/kg crocin-loaded D-MNPs. Each scale bar = 100 µm.
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Figure 57: Effects of 22 mg/kg crocin and its NP formulations on GST-P
expression in liver. a) Normal, b) DEN-induced, c) free 22 mg/kg crocin, and d)
22 mg/kg crocin-loaded D-MNPs. Each scale bar = 100 µm.
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Figure 58: Quantification of percent stained GST-P area in the two tested crocin
formulations. a) 11 mg/kg crocin-loaded D-MNPs, and b) 22 mg/kg crocin-loaded
D-MNPs. Values are expressed as mean ±SEM; *P ≤ 0.05, **P ≤ 0.01, ***P ≤
0.001.
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3.7.4.2. Ki-67 expression
Cell proliferation plays an important role in several steps of carcinogenesis
process. Initially carcinogens interact with DNA leading to mutant nucleotide
sequences. It’s however the induced proliferation of such mutant DNA that will lead
to the formation of pre-cancerous lesions, that would, at a later stage, form HCC
[236]. The examination of the presence of cell cycle-related proteins may yield
important information about the biological behavior of a tumor. Ki-67 is a nuclear
protein that has been used as proliferative marker of both normal and cancer cells. It
is expressed in all active phases of the cell cycle, including G1, S, G2, and mitosis,
with the highest expression seen in G2/M. Ki-67 is however lacking in resting cells
(G0). The name of ki-67 is derived from the city of origin (Kiel) and the number of
the original clone in the 96 well plate [237-241].
In the present study, Ki-67-specific antibody has been used to evaluate the
cellular proliferation rates and analyze liver regeneration and carcinogenesis
processes, in the different treated animal groups. Ki-67 immunoreactivity was
detected and localized in the nuclei of cells (Figures 59 and 60) and the IHC results
were quantified (Figure 61). Ki-67 expression was estimated as the percentage of
expression area that was stained by the antibody and visualized by DAB substrate as
dark-brown colour in 20 fields. In normal liver sections a limited number of Ki-67
positive cells was observed, but the number of Ki-67 positive cells was increased
significantly (P <0.0001) in DEN-induced liver tissues. According to Youssef et al.
the Ki-67 expression was increasing after 6 and 12 weeks. The highest increasing in
the number of Ki-67 positive cells was after 18 weeks post DEN injection with 75
and 100 mg/kg, each one a weeks for 3 weeks [241]. Also Narumi et al. observed
that the number of Ki-67-positive hepatocytes increased gradually after DEN
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exposure in time- and dose- dependent manner compared to control [235]. The
expression of Ki-67 positive cells in 11 and 22 mg/kg crocin-loaded D-MNPs groups
was reduced compared to DEN-induced or free crocin treated groups. Saffron
showed anti-proliferative activity by decreasing the number of Ki-67 positive cells in
DEN-treated rats. So this study indicated that attaching crocin on D-MNPs as a
delivery vehicle could enhance the anti-proliferative activities of crocin reported
earlier in [68].
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Figure 59: Effects of 11 mg/kg crocin and its NP formulations on Ki-67
expression in liver. a) Normal, b) DEN-induced, c) 11 mg/kg crocin, and d) 11
mg/kg crocin-loaded D-MNPs. Each scale bar = 100 µm.
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Figure 60: Effects of 22 mg/kg crocin and its NP formulations on Ki-67 expression
in liver. a) Normal, b) DEN-induced, c) 22 mg/kg crocin, and d) 22 mg/kg crocinloaded D-MNPs. Each scale bar = 100 µm.
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Figure 61: Estimated expression areas of Ki-67 positive cells in the two examined
crocin formulations. a) 11 mg/kg crocin-loaded D-MNPs, and b) 22 mg/kg crocinloaded D-MNPs. Values are expressed as mean ± SEM; * P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001.

177

3.7.4.3. M30-Cytodeath expression
Several studies indicate that apoptosis is essential in the modulation of
hepatocarcinogenesis and pre-neoplastic hepatocytes development. Apoptosis is a
physiological cell death that has been suggested to play an important role in the
maintenance of homeostasis [219, 220, 242-245].
Dysregulation of apoptosis is an important component of the multistage
hepatocarcinogenesis. This dysregulation may result in the decreased ability of cells
to undergo apoptosis and provide a selective survival advantage for those cells,
therefore leading to altered growth, cellular transformation and tumor progression.
During hepatocarcinogenesis, altered hepatic foci display increased rates of cell
proliferation and cell death relative to surrounding normal hepatocytes. This increase
in the apoptotic process, also called compensatory apoptosis, and occurs irrespective
of the oncogenic events generating pre-neoplastic and neoplastic lesions. However,
the rate of cell replication process exceeds the apoptosis leading to hyperplasia [219,
243, 246]. Some liver injury like chronic hepatitis is characterized by continuous
elimination of hepatic cells, which could lead to cancer formation by
cytolysis/regeneration phenomena [219, 243, 246].
Apoptotic pathways have been shown to be activated in several forms of
chronic liver injuries including liver cancer. Liver cell apoptosis can be initiated by
different complex pathways, the majority involving activation of the caspases.
Caspases-2, -8, -9, and -10 are initially activated and, in turn, activate a cascade of
downstream effector caspases such as -3,-6, and-7 [220, 242, 244].
Recently, there has been a growing interest in the role of cytokeratin proteins
during apoptosis. It has been suggested that caspase cleavage of the cytokeratin
proteins facilitate the formation of apoptotic bodies and amplify the apoptotic signal.
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Cytokeratin 18, for example, is an intermediate filament protein representing about
5% of total protein in the liver and other tissues such as pancreas and intestine.
During early apoptosis cytokeratin18 is cleaved by caspases 3 and 6 (Figure 62) at
two distinct sites (Aspartate 238 and Aspartate 396). This cleavage pattern is highly
specific to apoptosis and leads to the cellular release of caspase-cleaved cytokeratin
18 fragments into the extracellular space and finally to bloodstream causing the
characteristic morphologic changes of apoptosis [247, 248].
The computerized estimation of the cytokeratin positive cells has confirmed
the results of the IHC analysis of cytokeratin 18. As shown in Figures 63 and 64
normal group showed weak cytoplasmic cytokeratin 18 positive cells. This
expression increased significantly (P ≤ 0.001) in the DEN-induced compared to
normal group (Figure 65). The increasing in the apoptosis expression might be
because of the process of replacing the normal liver cells by pre-neoplastic cells.
This continuous elimination of hepatic cells could lead to cancer formation by
cytolysis/regeneration

phenomena.

The

increased

apoptosis,

also

called

compensatory apoptosis, occurs irrespective of the oncogenic events triggering preneoplastic and neoplastic lesions [219, 243]. Amin et al. demonstrated that saffron
treatment increased the number of M30-Cytodeath positive cells in DEN-induced
rats [68]. Moreover, the numbers of positive cells were increased in groups treated
with 11 mg/kg and 22 mg/kg crocin-loaded D-MNPs formulations compared with
DEN-induced group (P ≤ 0.001) or free crocin.
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Figure 62: Diagrammatic representation of caspases cleavage of the cytokeratin 18
[249].
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Figure 63: Effects of 11 mg/kg crocin and its NP formulations on M30-Cytodeath
expression in liver. a) Normal, b) DEN-induced, c) 11 mg/kg crocin, and d) 11
mg/kg crocin-loaded D-MNPs. Each scale bar = 100 µm.
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Figure 64: Effects of 22 mg/kg crocin and its NP formulations on M30-Cytodeath
expression in liver. a) Normal, b) DEN-induced, c) 22 mg/kg crocin, and d) 22
mg/kg crocin-loaded D-MNPs. Each scale bar = 100 µm.
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Figure 65: Estimated expression of M30-Cytodeath area in the two examined crocin
formulations. a) 11 mg/kg crocin-loaded D-MNPs, and b) 22 mg/kg crocin-loaded DMNPs. Values are expressed as mean ±SEM; * P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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3.7.4.4. Bcl-2 expression
Much attention has been given to the detection of molecular targets that are
also involved in the regulation of apoptosis and that might be altered in tumors. Bcl-2
oncogene was originally identified as overexpressed in most human B-cell follicular
lymphomas, caused by a chromosomal translocation involving chromosomes 14 and
18. The name of Bcl-2 is derived from B-cell lymphoma 2. Bcl-2 prolongs cell
survival by blocking apoptosis rather than regulation of cell replication. There are
several Bcl-2 family members that have been identified, including proteins that
induce apoptosis (pro-apoptotic), and those prevent apoptosis (anti-apoptotic). Proapoptotic proteins, includes Bax and Bak. The anti-apoptotic proteins such as Bcl2
and Bcl-XL. However, the cellular equilibrium between the promotor and the blocker
family members is known to be essential in determining cell fate (figure 66). Bcl-2 is
normally expressed in abundance in the thymus, spleen, and cerebrum but not in the
liver [219, 220, 243, 250-252].
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Figure 66: Diagrammatic representation of Bcl-2 and Bax regulate apoptosis,
modified from [253].
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Bcl-2 was shown to be overexpressed in DEN-induced mouse neoplasia
[250]. The objective of the present investigation was to determine whether
expression of Bcl-2 was altered in vivo following treatment with different crocin
formulations.
According to the IHC analysis (Figures 67 and 68) that was confirmed by
computerized analysis of 20 fields of IHC, most of the AHF in DEN-induced group
were positive for Bcl-2 and was significantly (P ≤ 0.001) increased compared to
normal group, which was weakly stained (Figure 69). The staining was specifically
seen in the cytoplasm of the cells. The expression of Bcl-2 in hepatic tissue of
normal animals could not be detect was examined by immunohistochemistry, but
positive staining of this protein was located in the cytoplasm of hepatocytes in
animals treated with 200 mg/kg DEN [254]. Also Lee et al. concluded that normal
mouse hepatocytes did not express Bcl-2, most DEN-induced tumours were positive
for this protein [251].
Sun et al. reported that animal injected i.p. with 6.25 and 25 mg/kg crocin
showed reduction in the tumour weight and size of HL-60 xenografts in nude mice.
These treated animals showed inhibited Bcl-2 expression, and increased Bax
expression in xenografts [208]. In the 11 and 22 mg/kg crocin-loaded D-MNPs
formulations, the expression of Bcl-2 positive cell in crocin-loaded D-MNPs was
reduced compared to DEN-induced or free crocin, indicating that the NPs could
induce

apoptosis

by

enhances

the

suppression

of

Bcl-2.
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Figure 67: Effects of 11 mg/kg crocin and its NP formulations on Bcl-2 expression in
liver. a) Normal, b) DEN-induced, c) 11 mg/kg crocin, and d) 11 mg/kg crocinloaded D-MNPs formulation. Each scale bar = 100 µm.
.
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Figure 68: Effects of 22 mg/kg crocin and its NP formulations on Bcl-2
expression in liver. a) Normal, b) DEN-induced, c) 22 mg/kg crocin and d) 22
mg/kg crocin-loaded D-MNPs formulation. Each scale bar = 100 µm.
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Figure 69: Quantitative analysis of Bcl-2 expression in relative to IHC fields in the
two tested crocin formulations. a) 11 mg/kg crocin-loaded D-MNPs, and b) 22
mg/kg crocin- loaded D-MNPs. Values are expressed as mean ±SEM; *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001.
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3.7.4.5. COX-2 expression
Liver cancer development is associated with chronic cytotoxic and
inflammatory events, indicating that inflammation mediators (such as prostaglandins)
are involved in its pathogenesis. Prostaglandins are produced from arachidonic acid
by either COX-1 or COX-2. COX-1 is normally and constantly expressed in most
tissues and is important for the maintenance of homeostatic functions. COX-2,
however, is an inducible enzyme that is normally associated with tumorigenesis
events, such as cell proliferation, angiogenesis, invasiveness and resistance to
apoptosis. Various studies have reported that increased COX-2 expression may
contribute to liver damage and tumorigenesis in animal models and HCC in humans.
As COX-2 is thought to contribute to inflammation-mediated cancer development,
the expression level of this enzyme has been reported in the different animal studies
[223, 255-257].
COX-2 has been localized to the neoplastic cells, endothelial cells, immune
cells, and stromal fibroblasts within the cancer. The downstream targets of COX-2
include: (1) production of VEGF ; (2) promotion of vascular sprouting, migration,
and tube formation; (3) enhanced endothelial cell survival via Bcl-2 expression and
Akt signaling; (4) induction of matrix metalloproteinases (MMP) 2 and 9, and (5)
activation of epidermal growth factor receptor-mediated angiogenesis [258].
In this study, IHC results of COX-2 (Figures 70 and 71) was quantified and
confirmed as shown in Figure 72. COX-2 expression was found to be significantly
increased (P ≤ 0.001) in DEN-induced group compared to normal group. Dietary
feeding with crocin (50-200 ppm) for 4 weeks was able to inhibit colonic
adenocarcinomas in mice and decrease the mRNA expression of inflammation
regulators such as COX-2, NF-κB, TNF-α, IL- 1β and IL-6 as reported by Kawabata
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et al. [259]. Therefore, free crocin has a role in inhibiting COX-2 expression in
animals with cancer. COX-2 expression was significantly reduced in crocin attached
D-MNPs of the 11 and 22 mg/kg formulations compared with DEN-induced (P ≤
0.001) or free crocin (P ≤ 0.001). These indicate the role of NPs in improving the
anti-cancer activity of crocin. COX-2 expression in all the treatment groups was
prominent staining around central vein and portal area.
Investigations by Sivaramakrishnan et al. [257], Amin et al. [68] and
Kawabata et al. [259] have shown nuclear translocation of NF-κB-p65 in DENinduced animals was important for the activation of COX-2 and thereby
inflammation and carcinogenesis. Thus, it is possible that crocin-loaded D-MNPs
suppress the nuclear localization of NF-κB p65 in DEN injected animals, thus
leading to the down-regulation of COX-2 and angiogenesis.
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Figure 70: Effects of 11 mg/kg crocin and its NP formulations on COX-2
expression in liver. a) Normal, b) DEN-induced, c) 11 mg/kg crocin and d) 11
mg/kg crocin-loaded D-MNPs. Each scale bar = 100 µm
.
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Figure 71: Effects of 22 mg/kg crocin and its NP formulations on COX-2
expression in liver. a) Normal, b) DEN-induced, c) 22 mg/kg crocin and d) 22
mg/kg crocin-loaded D-MNPs. Each scale bar = 100 µm.
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Figure 72: Estimated expression areas of COX-2 positive cells in the two
examined crocin formulations. a) 11 mg/kg crocin-loaded D-MNPs, and b) 22
mg/kg crocin-loaded D-MNPs.Values are expressed as mean ±SEM; *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001.
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3.7.4.6. VEGF expression
Angiogenesis is a complicated and critical process involving proliferation and
migration of endothelial cells to form new blood vessels. This phenomenon is
required for healing of injured tissue, and proliferation of tumor cells, in order to
supply the growth factors, nutrients, and oxygen. Recently, it was demonstrated that
angiogenesis starts at a very early (100-300 cells) stage of tumor formation. Various
angiogenic factors have been identified, but vascular endothelial growth factor
(VEGF) is the most potent and specific growth factor for angiogenesis. VEGF has
been demonstrated to play a critical role in division, migration, invasion and tubule
formation of vascular endothelial cells [260-265].
Chronic liver injury promotes the progress of genetic alterations leading to
dysplastic foci/nodule formation, which can develop into HCC later. Angiogenic
gene expression in the dysplastic foci facilitates the carcinogenesis pathway leading
to the highly vascularized lesion, which is characterized by the presence of sinusoidal
capillarization and subsequently, HCC development [260]. Several studies have been
shown that VEGF is secreted abundantly in several human tumors and animal
experimental models. VEGF-induced tumor development and angiogenesis are
mediated through several receptors, such as VEGFR2 and kinase insert domaincontaining

receptor/fetal

liver

kinase

1

(KDR/FLK-1).

Through

the

Ras/Raf/MEK/ERK pathway, activate VEGFr2 triggers cell cycle progression,
extracellular matrix remodeling, apoptosis resistance, and angiogenesis [260-264].
Proliferation of sinusoidal endothelial cells is mainly regulated by VEGF
[263]. Folkman was first to suggest that inhibiting angiogenesis might have
therapeutic potential for treating cancer [266] and since then many anti-angiogenic
agents have been introduced as potential therapeutic agents to block angiogenesis
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process [262]. In this study, the anti-angiogenic effects of crocin-loaded D-MNPs
have been investigated in comparison with free crocin.
VEGF IHC results (Figures 73 and 74) was quantified and confirmed as
shown in Figure 75. VEGF expression was significantly increased (P ≤ 0.001)
during hepatocarcinogenesis in DEN-induced group compared to normal group. This
was similar to the results of Liu et al. that demonstrated that VEGF expression, in
rats giving DEN at the dosage of 10 mg/kg every day for 16 weeks was highly
increased compared to normal animals [261].
Umigai et al. indicated that crocetin (aglycone of crocin carotenoids) might
suppress the VEGF-induced angiogenesis by inhibiting the phosphorylated-p38 and
protection of VE-cadherin expression [267]. Moreover, VEGF expression was
attenuated after the treatment with 11 and 22 mg/kg crocin-loaded D-MNPs
formulations compared to DEN-induced or free crocin. These data highlighted the
role

of

NPs

in

enhancing

the

anti-angiogenesis

activities

of

crocin.
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Figure 73: Effects of 11 mg/kg crocin and its NP formulations on VEGF expression
in liver. a) Normal, b) DEN-induced, c) 11 mg/kg crocin, and d) 11 mg/kg crocinloaded D-MNPs. Each scale bar = 100 µm.
.
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Figure 74: Effects of 22 mg/kg crocin and its NP formulations on VEGF expression
in liver. a) Normal, b) DEN-induced, c) 22 mg/kg crocin, and d) 22 mg/kg crocinloaded D-MNPs. Each scale bar = 100 µm.
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Figure 75: Quantitative analysis of VEGF-expression in the two
examined crocin formulations. a) 11 mg/kg crocin-loaded D-MNPs, and
b) 22 mg/kg crocin-loaded D-MNPs. Values are expressed as mean
±SEM; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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3.7.5. Proposed mechanism
To achieve effective targeting of pre-cancerous tissues, systemically delivered
NPs must first extravasate from the bloodstream and bind to cells. Then NPs must
cross the cell membrane of the target cells to reach appropriate intracellular sites.
Two targeting strategies, passive and active have been reported by researchers to
explain NPs delivery to the tumors. Active targeting, also called ligand-mediated
targeting, involves the utilization of specific ligands on the surface of NPs that bind
specific surface molecules or receptors overexpressed on the membranes of cancer
cells [90, 201-203, 268].
Passive targeting (used in this study) utilizes the distinctive pathological
characteristics of tumor blood vessels: highly immature, disorganized and dilated
with a high number of pores or fenestrae. These vascular changes may even lead to
the formation of wide gaps between endothelial cells and enabling NPs to
accumulate in pre-cancerous and cancerous tissues. Therefore, the 'leaky'
vascularization enhances permeability and allows migration and entry of NPs (10500 nm) into the pre-cancerous tissues (Figure 76). Moreover, the deficiency of the
lymphatic system in the newly formed pre-cancerous tissue does not allow the
recapture of these NPs and improves the retention or preservation effect [90, 201203].
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Figure 76: A diagram representing the changes that occur in bile ductule and oval
cells due to DEN. Proliferation of oval cells leads to evagination of the
epithelium and formation of pre-cancerous lesion. New blood vessels also develop
(angiogenesis) around the hyperplastic tissue. These changes might lead to
enhanced internalization of crocin-loaded D-MNPs by passive targeting.
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Once extravasated from the bloodstream, D-MNPs internalization into the
oval cells and hepatocytes starts by their binding or adsorption to cell membranes
followed by the formation of endocytotic vesicles or NPs-containing endosomes
[269]. Thus, it is possible that in this study, endosomes and lysosomes fuse to form
endo-lysosome vesicles in which the crocin is released from crocin-loaded D-MNPs
in its active form as illustrated in Figure 77. Most of the NPs were captured by
kupffer cells via phagocytosis (Figure 55), and then the formation of a phagosome.
Phago-lysosome is formed after fusion of phagosome with lysosome, where the
crocin is also released from crocin-loaded D-MNPs in its active form.
Dextran will be degraded into sugar components and MNPs will be degraded
into free iron II and III. Free Iron in the hepatocytes cytoplasm can be used in
essential physiological functions, such as mitochondrial adenosine triphosphate
(ATP) generation and DNA damage repair. Meanwhile, unused iron is stored in the
iron-binding protein such as ferritin, hemosiderin, and transferrin. Iron might exit
the cells by exocytosis, bind to transferrin in blood, and get transported throughout
the body as diferric transferrin. Iron homeostasis is preserved by the loss of about 1
mg of iron per day through the sloughing of intestinal mucosa and skin. On the other
hand, 20–25 mg of iron is essential each day for the hemoglobinization of new
erythrocytes [270].
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Figure 77: A diagram representing the proposed steps of endocytosis of crocinloaded D-MNPs into the oval cell and hepatocytes. The NPs go through (1) cellular
association, (2) internalization of via endocytosis, (3) endosomal escape or (4)
lysosomal degradation, (5) free crocin release into the cytoplasm and D-MNPs
biodegradation, (6) cytoplasmic transport of crocin to effect organelles such as
nucleus and mitochondria, modified from [271].
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Moreover, the microenvironment surrounding pre-cancerous tissue is
different from healthy tissue, a physiological phenomenon that also supports passive
targeting. Due to high metabolic rate of fast-growing tumor cells, they require more
oxygen and nutrients. Consequently, glycolysis is stimulated to obtain extra energy,
resulting in an acidic environment. The passive diffusion mechanism will facilitate
the crocin-loaded D-MNPs entry to the acidic environment of cells thus releasing
crocin in its active form.
The present study shows that the crocin release rate in acidic cancerous
condition was higher than the physiological condition (pH 7.4) as in Figure 44. This
fast crocin release could be explained by induced hydrolysis [3, 200, 272] of ester
bond between crocin and cross-linker conjugated to D-MNPs in the acidic
microenvironment. Following the successful loading and releasing of crocin in its
active from D-MNPs in pre-cancerous lesions location, crocin can affects such
lesions via different mechanisms; some of these mechanisms have been investigated
in this study. Crocin could decrease GST-P expression in DEN-induced mice
(Figure 58). This reduced level of GST-P might be due to crocin’s anti-antioxidant
effect though suppressing the DEN-induced ROS. Ochiai et al. reported that crocin is
considered promising for neuroprotection due to their potential ROS-suppressing
abilities. Treatment of PC-12 cells with crocin has been reported to inhibit cell
membrane lipid peroxidation and to restore intracellular superoxide dismutase and
glutathione peroxidase (anti-oxidant enzymes) activity [273].
The anti-proliferative activity of crocin in this study was also associated with
the inhibition of Ki-67 (Figure 61) and induction of apoptosis. Crocin stimulated
apoptosis by up-regulation of caspase cleaved cytokeratin 18 (Figure 65) and downregulation of Bcl-2 expression (Figure 69). Crocin might reduce the Bcl-2 through
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de-activating PI3K/AKT signaling pathway [274]. Other studies showed that crocin
induced broad changes in the expression profile of genes modulating cell cycle via
down-regulating the

Bcl-2

expression and up-regulating Bax

expression.

Furthermore, crocin has been shown to increase the number of cells at G0/G1 phase,
thus increasing the percentage of apoptotic cells through G1 cell cycle arrest [67,
207, 275].
Liver cancer development is combined with chronic cytotoxicity and
inflammation. In this study, crocin displayed an efficacy in significantly reducing
DEN-induced liver inflammation by decreasing level of expression COX-2 in the
cells as in Figure 72. COX-2 is a key enzyme involved in producing inflammatory
signals [276]. The overall proposed anti-cancer mechanisms of crocin are shown in
Figure 78.
To our knowledge this study is the first to show that crocin has an inhibitory
effect against angiogenesis and does significantly decreases VEGF expression in
DEN-induced mice (Figure 75). This effect might be because of suppression of p38
phosphorylation similar to crocetin [267].
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Figure 78: Diagrammatic representation demonstrating the proposed anti-cancer
activity of crocin on pre-cancer/cancer cell, in vitro and in vivo. Crocin has multieffects on the cell include inhibition of proliferation and inflammation and
enhancement of apoptosis. Crocin exhibits inhibitory effect on proliferation by
decreasing Ki-67 nuclear protein, while apoptosis activity increases through upregulation of caspase cleaved cytokeratin 18 and down-regulation of Bcl-2. The
anti-inflammatory and anti-angiogenesis effect of crocin is due to down-regulation
of COX-2. Anti-angiogenesis also includes inhibition of VEGF growth factor.
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Chapter 4: Conclusions

HCC is one of the most widespread cancers worldwide and its incidence and
mortality rate are on the rise in many countries. The major drawbacks in current
modalities of liver cancer treatment are associated with high toxicity and the lack of
specificity to cancer cells. Thus, different controlled drug delivery systems have been
developed and natural anti-cancer sources have been investigated to overcome those
shortcomings. Modified co-precipitation method in air at low temperature was used
to manufacture pure and coated MNPs. After investigating different reaction
parameters and coating materials, 1.0 % of dextran was selected as an ideal coating
material using a slow feeding rate at 40 ml/hr while maintaining the stirring and
soaking temperatures at 60ºC. Crocin was chemically conjugated to D-MNPs via
cross-linker. Crocin is a saffron-based natural product that has shown anti-tumour
activity both in vitro and in vivo.
To our knowledge this is the first report indicating that i.v. administration and
the controlled release of crocin conjugated onto D-MNPs could improve the anticancer therapeutic effect than free crocin in in vitro and in vivo liver cancer models.
HepG2 cells treated with crocin-loaded D-MNPs reduced the cell proliferation when
compared to control (non-treated cells) or those treated with free crocin or D-MNPs.
In mice injected with diethylnitosamine, and developed several pre-cancerous
changes and microscopic intrahepatic cholangioma, immunohistochemical results
indicated that D-MNPs conjugated with crocin could increase the anti-cancer activity
over free crocin. Thus, to obtain an optimal dose for use in humans, these NPs
require further investigation. These results provide insights for designing new
modalities for treatment of liver cancer which would hopefully reduce its high
mortality rate.
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Chapter 5: Future Prospects and Limitations

To reduce the toxic side effects induced by traditional chemotherapy, this
dissertation demonstrated a potential means of passive delivery for crocin as a
natural anti-cancer agent specifically into cancer sites. With the promising anticancer results of crocin attached on D-MNPs reported in this study both in vitro and
in vivo, it would be useful to investigate other pathways and possible mechanisms by
which crocin in this NPs system could inhibit the cancer development. Key markers
of pathways of interest include, but not limited to, p53 and caspase 3 for apoptosis,
and NF-κB, IL-1ß, IL-6 and TNF-α for inflammation.
In addition, it would be interesting to evaluate the effect of crocin-attached DMNPs system on other cell lines and in different animal models of HCC. Hep3B,
SUN-398 and PLHC-1 are examples of other HCC cell lines. Alternative HCC
animal models include chemically-induced with aflatoxin B1 or carbon tetrachloride,
xenograft model, and transgenic mice such as TAg mice. Being synthesized with
magnetite cores would make it beneficial to track these nano-carrier using MRI while
simultaneously acting as anti-cancer agent in vitro and in vivo. MRI can be used to
evaluate the reduction in cancer tissues after treating with crocin-load D-MNPs.
Despite the success of developing D-MNPs that enhanced the delivery and
activity of crocin, there are still several obstacles to be overcome. First, there was
minor cytotoxicity because of de-attachment of dextran as a coating material
exposing MNPs core to the cells. Second, crocin release rate was slow and took two
weeks to reach 92% at pH 5.5. Third, there was difficulty to reproduce the effective
crocin-loaded D-MNPs due to fact that not all MNPs could be coated with dextran
and attached to crocin similarly and effectively (heterogeneous production).
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Further refinements are needed for these NPs to be used for drug delivery. In
spite of that, the developed D-MNPs have important properties that qualify them to
be used for cancer treatment, such as, hyperthermia.
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